PRODUCT MONOGRAPH

**PrIMITREX DF**
(sumatriptan succinate tablets)
50 mg and 100 mg sumatriptan

**PrIMITREX**
(sumatriptan succinate injection)
6 mg sumatriptan
Subcutaneous Injection and Autoinjector

**PrIMITREX**
(sumatriptan nasal spray)
5 mg and 20 mg sumatriptan (as hemisulphate)

5-HT$_1$ Receptor Agonist

Migraine Therapy

GlaxoSmithKline Inc.  Date of Revision: July 24, 2014
7333 Mississauga Road
Mississauga, Ontario
L5N 6L4

Submission Control No: 174758

©2014 GlaxoSmithKline, All Rights Reserved
* IMITREX DF is a registered trademark, used under license by GlaxoSmithKline Inc.
* IMITREX is a registered trademark, used under license by GlaxoSmithKline Inc.
* IMITREX STATdose Pen and IMITREX STATdose System are registered trademarks, used under license by GlaxoSmithKline Inc.
# Table of Contents

## PART I: HEALTH PROFESSIONAL INFORMATION
- Summary Product Information ........................................ 3
- Indications and Clinical Use ........................................ 4
- Contraindications ....................................................... 4
- Warnings and Precautions ........................................... 5
- Adverse Reactions ..................................................... 12
- Drug Interactions ..................................................... 16
- Dosage and Administration ......................................... 17
- Overdosage .............................................................. 20
- Action and Clinical Pharmacology ............................... 21
- Storage and Stability ................................................ 23
- Dosage Forms, Composition and Packaging ................. 23

## PART II: SCIENTIFIC INFORMATION
- Pharmaceutical Information ....................................... 24
- Clinical Trials .......................................................... 25
- Detailed Pharmacology ............................................. 30
- Toxicology ............................................................... 33
- References ............................................................... 40

## PART III: CONSUMER INFORMATION
- ............................................................................. 43
- ............................................................................. 47
- ............................................................................. 54
**IMITREX DF®**
(sumatriptan succinate tablets)
50 mg and 100 mg sumatriptan

**IMITREX®**
(sumatriptan succinate injection)
6 mg sumatriptan
Subcutaneous Injection and Autoinjector

**IMITREX®**
(sumatriptan nasal spray)
5 mg, 20 mg sumatriptan (as hemisulphate)

**PART 1: HEALTH PROFESSIONAL INFORMATION**

**SUMMARY PRODUCT INFORMATION**

<table>
<thead>
<tr>
<th>Route of Administration</th>
<th>Dosage Form / Strength</th>
<th>Nonmedicinal Ingredients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral</td>
<td>(sumatriptan succinate) Tablets 50 mg and 100 mg</td>
<td>croscarmellose sodium, dibasic calcium phosphate anhydrous, iron oxide red (100 mg only), magnesium stearate, methylhydroxypropyl cellulose, microcrystalline cellulose, sodium bicarbonate, titanium dioxide and triacetin.</td>
</tr>
<tr>
<td>Subcutaneous</td>
<td>(sumatriptan succinate) Subcutaneous Injection and Autoinjector 6 mg</td>
<td>isotonic sodium chloride solution containing water for injection.</td>
</tr>
<tr>
<td>Intranasal</td>
<td>(sumatriptan hemisulphate) Nasal Spray 5 mg and 20 mg</td>
<td>anhydrous dibasic sodium phosphate, monobasic potassium phosphate, purified water, sodium hydroxide and sulphuric acid.</td>
</tr>
</tbody>
</table>
INDICATIONS AND CLINICAL USE

**Adults**
IMITREX DF® (sumatriptan succinate) and IMITREX® (sumatriptan succinate/sumatriptan hemisulphate) are indicated for the acute treatment of migraine attacks with or without aura.

IMITREX DF® and IMITREX® are not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic, basilar, or ophthalmoplegic migraine (see CONTRAINDICATIONS). Safety and efficacy have not been established for cluster headache, which is present in an older, predominantly male population.

**Pediatrics (< 18 years of age)**
The safety and efficacy of IMITREX DF® and IMITREX® in children have not been established and their use in this age group is not recommended. (See WARNINGS and PRECAUTIONS).

**Geriatrics (> 65 years of age)**
Experience of the use of IMITREX DF® and IMITREX® in patients aged over 65 years is limited. Therefore the use of IMITREX DF® and IMITREX® in patients over 65 years is not recommended. (See WARNINGS and PRECAUTIONS).

CONTRAINDICATIONS

IMITREX DF® and IMITREX® are contraindicated in patients with history, symptoms, or signs of ischemic cardiac, cerebrovascular, or peripheral vascular syndromes, valvular heart disease or cardiac arrhythmias (especially tachycardias). In addition, patients with other significant underlying cardiovascular diseases (e.g., atherosclerotic disease, congenital heart disease) should not receive IMITREX DF® or IMITREX®. Ischemic cardiac syndromes include, but are not limited to, angina pectoris of any type (e.g., stable angina of effort and vasospastic forms of angina such as the Prinzmetal’s variant), all forms of myocardial infarction, and silent myocardial ischemia. Cerebrovascular syndromes include, but are not limited to, strokes of any type as well as transient ischemic attacks (TIAs). Peripheral vascular disease includes, but is not limited to, ischemic bowel disease, or Raynaud’s syndrome (see WARNINGS AND PRECAUTIONS).

Because IMITREX DF® and IMITREX® may increase blood pressure, they are contraindicated in patients with uncontrolled or severe hypertension.

Concurrent administration of MAO inhibitors or use within 2 weeks of discontinuation of MAO inhibitor therapy is contraindicated (see ACTION AND CLINICAL PHARMACOLOGY and DRUG INTERACTIONS).
Ergot-containing drugs have been reported to cause prolonged vasospastic reactions. Because IMITREX DF® and IMITREX® may also cause coronary vasospasm and these effects may be additive, the use of IMITREX DF® and IMITREX® within 24 hours before or after treatment with other 5-HT1 receptor agonists, or ergotamine-containing drugs or their derivatives (e.g. dihydroergotamine, methysergide) is contraindicated.

IMITREX DF® and IMITREX® should not be administered to patients with severe hepatic impairment (see WARNINGS AND PRECAUTIONS, Special Populations and DOSAGE AND ADMINISTRATION).

IMITREX DF® and IMITREX® are contraindicated in patients with hemiplegic, basilar, or ophthalmoplegic migraine.

IMITREX DF® and IMITREX® are contraindicated in patients with hypersensitivity to sumatriptan or to any of the ingredients of the formulations, or component of the container. For a complete listing, see the DOSAGE FORMS, COMPOSITION AND PACKAGING section of the product monograph.

IMITREX® Injection should not be given intravenously because of its potential to cause coronary vasospasm.

WARNINGS AND PRECAUTIONS

General

IMITREX DF® and IMITREX® should only be used where a clear diagnosis of migraine has been established.

Cluster Headache: There is insufficient information on the efficacy and safety of IMITREX DF® and IMITREX® in the treatment of cluster headache, which is present in an older, predominantly male population. The need for prolonged use and the demand for repeated medication in this condition renders the dosing information inapplicable for cluster headache.

Psychomotor Impairment: Patients should be cautioned that drowsiness may occur as a result of treatment with IMITREX DF® and IMITREX®. They should be advised not to perform skilled tasks (e.g. driving or operating machinery) if drowsiness occurs.

Medication Overuse Headache: Overuse of acute headache treatments has been associated with the exacerbation of headache (medication overuse headache, MOH) in susceptible patients. Withdrawal of the treatment may be necessary.
Cardiovascular

Risk of Myocardial Ischemia and/or Infarction and Other Adverse Cardiac Events:

IMITREX® has been associated with transient chest and/or neck pain, pressure, heaviness and tightness which may resemble angina pectoris. In rare cases, the symptoms have been identified as being the likely result of coronary vasospasm or myocardial ischemia. Rare cases of serious coronary events or arrhythmia have occurred following use of IMITREX®. IMITREX DF® and IMITREX® should not be given to patients who have documented ischemic or vasospastic coronary artery disease (CAD) (see CONTRAINDICATIONS). It is strongly recommended that IMITREX DF® and IMITREX® not be given to patients in whom unrecognized CAD is predicted by the presence of risk factors (e.g., hypertension, hypercholesterolemia, smoking, obesity, diabetes, strong family history of CAD, female who is surgically or physiologically postmenopausal, or male who is over 40 years of age) unless a cardiovascular evaluation provides satisfactory clinical evidence that the patient is reasonably free of coronary artery and ischemic myocardial disease or other significant underlying cardiovascular disease. The sensitivity of cardiac diagnostic procedures to detect cardiovascular disease or predisposition to coronary artery vasospasm is unknown. If, during the cardiovascular evaluation, the patient’s medical history or electrocardiographic investigations reveal findings indicative of, or consistent with, coronary artery vasospasm or myocardial ischemia, IMITREX DF® or IMITREX® should not be administered (see CONTRAINDICATIONS).

For patients with risk factors predictive of CAD who are considered to have a satisfactory cardiovascular evaluation, the first dose of IMITREX DF® or IMITREX® should be administered in the setting of a physician’s office or similar medically staffed and equipped facility. Because cardiac ischemia can occur in the absence of clinical symptoms, consideration should be given to obtaining electrocardiograms in patients with risk factors during the interval immediately following IMITREX DF® or IMITREX® administration on the first occasion of use. However, an absence of drug-induced cardiovascular effects on the occasion of the initial dose does not preclude the possibility of such effects occurring with subsequent administrations.

Intermittent long term users of IMITREX DF® or IMITREX® who have or acquire risk factors predictive of CAD as described above, should receive periodic interval cardiovascular evaluations over the course of treatment.

If symptoms consistent with angina occur after the use of IMITREX DF® or IMITREX®, ECG evaluation should be carried out to look for ischemic changes.
The systematic approach described above is intended to reduce the likelihood that patients with unrecognized cardiovascular disease will be inadvertently exposed to IMITREX DF® or IMITREX®.

Discomfort in the chest, neck, throat and jaw (including pain, pressure, heaviness, tightness, dyspnea) has been reported after administration of IMITREX®. Because 5-HT1 agonists may cause coronary vasospasm, patients who experience signs or symptoms suggestive of angina following IMITREX DF® or IMITREX® should be evaluated for the presence of CAD or a predisposition to variant angina before receiving additional doses, and should be monitored electrocardiographically if dosing is resumed and similar symptoms recur. Similarly, patients who experience other symptoms or signs suggestive of decreased arterial flow, such as ischemic bowel syndrome or Raynaud’s syndrome, following IMITREX DF® or IMITREX® should be evaluated for atherosclerosis or predisposition to vasospasm (see CONTRAINDICATIONS and WARNINGS and PRECAUTIONS and ADVERSE DRUG REACTIONS, Clinical Trial Adverse Drug Reactions).

Cardiac Events and Fatalities Associated with 5-HT1 Agonists:
IMITREX DF® and IMITREX® can cause coronary artery vasospasm. Serious adverse cardiac events, including acute myocardial infarction, life-threatening disturbances of cardiac rhythm, and death have been reported within a few hours following the administration of 5-HT1 agonists. Considering the extent of use of 5-HT1 agonists in patients with migraine, the incidence of these events is extremely low. The fact that some of these events have occurred in patients with no prior cardiac disease history and with documented absence of CAD, and the close proximity of the events to IMITREX® use support the conclusion that some of these cases were caused by the drug. In many cases, however, where there has been known underlying coronary artery disease, the relationship is uncertain.

Premarketing Experience With IMITREX®:
Of 6348 patients with migraine who participated in premarketing controlled and uncontrolled clinical trials of oral and IMITREX®, two experienced clinical adverse events shortly after receiving oral IMITREX® that may have reflected coronary vasospasm. Neither of these adverse events was associated with a serious clinical outcome.

Among the more than 1900 patients with migraine who participated in premarketing controlled clinical trials of subcutaneous IMITREX®, there were eight patients who sustained clinical events during or shortly after receiving IMITREX®, that may have reflected coronary artery vasospasm. Six of these eight patients had ECG changes consistent with transient ischemia, but without accompanying clinical symptoms or signs. Of these eight patients, four had either findings suggestive of CAD or risk factors predictive of CAD prior to study enrolment.
Among approximately 4,000 patients with migraine who participated in premarketing controlled and uncontrolled clinical trials of IMITREX® Nasal Spray, one patient experienced an asymptomatic subendocardial infarction possibly subsequent to a coronary vasospastic event.

Postmarketing Experience With IMITREX®:
Serious cardiovascular events, some resulting in death, have been reported in association with the use of IMITREX® Injection or IMITREX® Tablets. The uncontrolled nature of postmarketing surveillance, however, makes it impossible to determine definitively the proportion of the reported cases that were actually caused by IMITREX® or to reliably assess causation in individual cases. On clinical grounds, the longer the latency between the administration of IMITREX® and the onset of the clinical event, the less likely the association is to be causative. Accordingly, interest has focused on events beginning within 1 hour of the administration of IMITREX®.

Cardiac events that have been observed to have onset within 1 hour of IMITREX® administration include: coronary artery vasospasm, transient ischemia, myocardial infarction, ventricular tachycardia and ventricular fibrillation, cardiac arrest, and death.

Some of these events occurred in patients who had no findings of CAD and appear to represent consequences of coronary artery vasospasm. However, among reports from the USA of serious cardiac events occurring within 1 hour of IMITREX® administration, almost all of the patients had risk factors predictive of CAD and the presence of significant underlying CAD was established in most cases (see CONTRAINDICATIONS).

Cerebrovascular Events and Fatalities with 5-HT1 Agonists:
Cerebral hemorrhage, subarachnoid hemorrhage, stroke, and other cerebrovascular events have been reported in patients treated with oral or subcutaneous IMITREX®, and some have resulted in fatalities. The relationship of IMITREX® to these events is uncertain. In a number of cases, it appears possible that the cerebrovascular events were primary, IMITREX® having been administered in the incorrect belief that the symptoms experienced were a consequence of migraine when they were not. Before treating migraine headaches with IMITREX DF® and IMITREX® in patients not previously diagnosed as migraineurs, and in migraineurs who present with atypical symptoms, care should be taken to exclude other potentially serious neurological conditions. If a patient does not respond to the first dose, the opportunity should be taken to review the diagnosis before a second dose is given. It should also be noted that patients with migraine may be at increased risk of certain cerebrovascular events (e.g., stroke, hemorrhage, TIA).

Special Cardiovascular Pharmacology Studies:
In subjects (n=10) with suspected coronary artery disease undergoing angiography, a 5-HT1 agonist at a subcutaneous dose of 1.5 mg produced an 8% increase in aortic blood pressure, an 18% increase in pulmonary artery blood pressure, and an 8% increase in systemic vascular resistance. In addition, mild chest pain or tightness was reported by four subjects. Clinically significant increases in blood pressure were experienced by
three of the subjects (two of whom also had chest pain/discomfort). Diagnostic angiogram results revealed that 9 subjects had normal coronary arteries and 1 had insignificant coronary artery disease.

In an additional study with this same drug, migraine patients (n=35) free of cardiovascular disease were subjected to assessments of myocardial perfusion by positron emission tomography while receiving a subcutaneous 1.5 mg dose in the absence of a migraine attack. Reduced coronary vasodilatory reserve (~10%), increase in coronary resistance (~20%), and decrease in hyperemic myocardial blood flow (~10%) were noted. The relevance of these findings to the use of the recommended oral doses of this 5-HT\textsubscript{1} agonist is not known.

Similar studies have not been done with IMITREX DF\textsuperscript{®} or IMITREX\textsuperscript{®}. However, owing to the common pharmacodynamic actions of 5-HT\textsubscript{1} agonists, the possibility of cardiovascular effects of the nature described above should be considered for any agent of this pharmacological class.

**Other Vasospasm-Related Events:** 5-HT\textsubscript{1} agonists may cause vasospastic reactions other than coronary artery vasospasm. Extensive post-market experience has shown the use of IMITREX\textsuperscript{®} to be associated with rare occurrences of peripheral vascular ischemia and colonic ischemia with abdominal pain and bloody diarrhea, and in isolated cases there was no previous history or concomitant medications.

**Increase in Blood Pressure:** Significant elevation in blood pressure, including hypertensive crisis, has been reported on rare occasions in patients with and without a history of hypertension. IMITREX DF\textsuperscript{®} and IMITREX\textsuperscript{®} are contraindicated in patients with uncontrolled or severe hypertension (see CONTRAINDICATIONS). In patients with controlled hypertension, IMITREX DF\textsuperscript{®} or IMITREX\textsuperscript{®} should be administered with caution, as transient increases in blood pressure and peripheral vascular resistance have been observed in a small portion of patients.

**Immune**

Rare hypersensitivity (anaphylaxis/anaphylactoid) reactions may occur in patients receiving 5-HT\textsubscript{1} agonists such as IMITREX DF\textsuperscript{®} or IMITREX\textsuperscript{®}. Such reactions can be life-threatening or fatal. In general, hypersensitivity reactions to drugs are more likely to occur in individuals with a history of sensitivity to multiple allergens (see CONTRAINDICATIONS). Owing to the possibility of cross-reactive hypersensitivity reactions, IMITREX DF\textsuperscript{®} and IMITREX\textsuperscript{®} should not be used in patients having a history of hypersensitivity to chemically related 5-HT\textsubscript{1} receptor agonists. There have been reports of patients with known hypersensitivity to sulphonamides exhibiting an allergic reaction following administration of IMITREX\textsuperscript{®}. Reactions ranged from cutaneous hypersensitivity to anaphylaxis.
**Neurologic**

Care should be taken to exclude other potentially serious neurologic conditions before treating headache in patients not previously diagnosed with migraine headache or who experience a headache that is atypical for them. There have been rare reports where patients received 5-HT1 agonists for severe headaches that were subsequently shown to have been secondary to an evolving neurologic lesion. For newly diagnosed patients or patients presenting with atypical symptoms, the diagnosis of migraine should be reconsidered if no response is seen after the first dose of IMITREX DF® or IMITREX®.

**Seizures:** Caution should be observed if IMITREX DF® or IMITREX® is to be used in patients with a history of seizures or other risk factors, such as structural brain lesions, which lower the convolution threshold. There have also been rare post-market reports of seizures following administration of IMITREX® in patients without risk factors or previous history of seizures. (See ADVERSE REACTIONS, Post Market Adverse Drug Reactions, Nervous System Disorders.)

**Selective Serotonin Reuptake Inhibitors (SSRIs)/Serotonin Norepinephrine Reuptake Inhibitors (SNRIs) and Serotonin Syndrome:** Cases of life-threatening serotonin syndrome have been reported during combined use of selective serotonin reuptake inhibitors (SSRIs)/serotonin norepinephrine reuptake inhibitors (SNRIs) and triptans. If concomitant treatment with IMITREX DF® or IMITREX® and SSRIs (e.g., fluoxetine, paroxetine, sertraline) or SNRIs (e.g., venlafaxine) is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases. Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, coma), autonomic instability (e.g., tachycardia, labile blood pressure, hyperthermia), neuromuscular aberrations (e.g., hyperreflexia, incoordination) and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea) (see DRUG INTERACTIONS, SSRIs/SNRIs).

**Ophthalmologic**

**Binding to Melanin Containing Tissues:** In rats treated with a single subcutaneous dose (0.5 mg/kg) or oral dose (2 mg/kg) of radiolabeled sumatriptan, the elimination half life of radioactivity from the eye was 15 and 23 days, respectively, suggesting that sumatriptan and/or its metabolites bind to the melanin of the eye. Because there could be an accumulation in melanin rich tissues over time, this raises the possibility that sumatriptan could cause toxicity in these tissues after extended use. However, no effects on the retina related to treatment with sumatriptan were noted in any of the oral or subcutaneous toxicity studies. Although no systematic monitoring of ophthalmologic function was undertaken in clinical trials, and no specific recommendations for ophthalmologic monitoring are offered, prescribers should be aware of the possibility of long term ophthalmologic effects.
Special Populations

Pregnant Women: Reproduction studies, performed in rats, have not revealed any evidence of impaired fertility, teratogenicity, or postnatal development due to IMITREX®. Reproduction studies, performed in rabbits by the oral route, have shown increased incidence of variations in cervico-thoracic blood vessel configuration in the fetuses. These effects were only seen at the highest dose tested, which affected weight gain in the dams, and at which blood levels were in excess of 50 times those seen in humans after therapeutic doses. A direct association with IMITREX DF® or IMITREX® treatment is considered unlikely but cannot be excluded.

Post-marketing data from multiple prospective pregnancy registries have documented the pregnancy outcomes in approximately 1,100 women exposed to sumatriptan. At this time, there is insufficient information to draw conclusions. Therefore, use of IMITREX DF® and IMITREX® is not recommended in pregnancy and it should be used only if the potential benefit to the mother justifies the potential risk to the fetus.

In a rat fertility study, oral doses of IMITREX® resulting in plasma levels approximately 150 times those seen in humans after a 6 mg subcutaneous dose and approximately 200 times those seen in humans after a 100 mg oral dose were associated with a reduction in the success of insemination. This effect did not occur during a subcutaneous study, where maximum plasma levels achieved approximately 100 times those in humans by the subcutaneous route and approximately 150 times those in humans by the oral route.

Nursing Women: Sumatriptan is excreted in human breast milk. Therefore, caution is advised when administering IMITREX DF® or IMITREX® to nursing women. Infant exposure can be minimized by avoiding breast-feeding for 24 hours after treatment.

Pediatrics (< 18 years of age): The safety and efficacy of IMITREX DF® or IMITREX® in children has not been established and its use in this age group is not recommended.

Geriatrics (> 65 years of age): Experience of the use of IMITREX DF® or IMITREX® in patients aged over 65 years is limited. Therefore the use of IMITREX DF® or IMITREX® in patients over 65 years is not recommended.

Hepatic Impairment: The effect of hepatic impairment on the efficacy and safety of IMITREX DF® and IMITREX® has not been evaluated; however, the pharmacokinetic profile of sumatriptan in patients with moderate hepatic impairment (Child Pugh B) shows that these patients, following an oral dose of 50 mg, have much higher plasma sumatriptan concentrations than healthy subjects (Table 1). A similar increase would be expected following intranasal administration. Therefore, oral and intranasal doses of sumatriptan are not recommended in patients with mild or moderate hepatic impairment (Child Pugh A or B) (see DOSAGE AND ADMINISTRATION).

---

1 Assessed by aminopyrine breath test (>0.2-0.4 scaling units)
Table 1  Pharmacokinetic Parameters After Oral Administration of IMITREX®
50 mg to Healthy Volunteers and Moderately Hepatically Impaired Patients

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Mean Ratio (hepatic impaired/healthy) n=8</th>
<th>90% CI</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>(AUC_\infty)</td>
<td>181%</td>
<td>130 to 252%</td>
<td>0.009*</td>
</tr>
<tr>
<td>(C_{\text{max}})</td>
<td>176%</td>
<td>129 to 240%</td>
<td>0.007*</td>
</tr>
</tbody>
</table>

*Statistically significant

The pharmacokinetic parameters of 6 mg subcutaneous sumatriptan do not differ statistically between normal volunteers and moderately hepatically impaired subjects (Child Pugh B). All formulations of sumatriptan are contraindicated in patients with severe hepatic impairment (see CONTRAINDICATIONS and DOSAGE AND ADMINISTRATION).

Renal: The effects of renal impairment on the efficacy and safety of IMITREX DF® and IMITREX® have not been evaluated. Therefore, IMITREX DF® and IMITREX® are not recommended in this patient population.

Monitoring and Laboratory Tests
No specific laboratory tests are recommended for monitoring patients prior to and/or after treatment with IMITREX DF® or IMITREX®.

ADVERSE REACTIONS

Serious cardiac events, including some that have been fatal, have occurred following the use of 5-HT\(_1\) agonists. These events are extremely rare and most have been reported in patients with risk factors predictive of CAD. Events reported have included coronary artery vasospasm, transient myocardial ischemia, myocardial infarction, ventricular tachycardia, and ventricular fibrillation (see CONTRAINDICATIONS and WARNINGS and PRECAUTIONS).

Clinical Trial Adverse Drug Reactions

Because clinical trials are conducted under very specific conditions the adverse reaction rates observed in the clinical trials may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse drug reaction information from clinical trials is useful for identifying drug-related adverse events and for approximating rates.

Experience in Controlled Clinical Trials with IMITREX®

Typical 5-HT\(_1\) Agonist Adverse Reactions: As with other 5-HT\(_1\) agonists, IMITREX® has been associated with sensations of heaviness, pressure, tightness or pain, which may
be intense. These may occur in any part of the body including the chest, throat, neck, jaw and upper limb.

**Acute Safety:** In placebo-controlled migraine trials, 7,668 patients received at least one dose of IMITREX® (3095 oral, 1432 subcutaneous, 3141 intranasal). The following tables (Table 2, Table 3, Table 4) list adverse events occurring in these trials at an incidence of 1% or more in any of the IMITREX® dose groups and that occurred at a higher incidence than in the placebo groups.

**Table 2 Treatment-Emergent Adverse Events in Oral Placebo-Controlled Clinical Trials Reported by at Least 1% of Patients with Migraine**

<table>
<thead>
<tr>
<th>Symptom</th>
<th>Placebo</th>
<th>IMITREX® 25 mg</th>
<th>IMITREX® 50 mg</th>
<th>IMITREX® 100 mg**</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of Patients</td>
<td>690</td>
<td>351</td>
<td>723</td>
<td>2021</td>
</tr>
<tr>
<td>Number of Migraine Attacks Treated</td>
<td>1187</td>
<td>945</td>
<td>1889</td>
<td>14750</td>
</tr>
<tr>
<td>Symptoms of Potentially Cardiac Origin</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Chest Sensations*</td>
<td>0.6%</td>
<td>2.3%</td>
<td>2.6%</td>
<td>3.2%</td>
</tr>
<tr>
<td>• Neck/Throat/Jaw Sensations*</td>
<td>1.4%</td>
<td>2.3%</td>
<td>3.5%</td>
<td>5.2%</td>
</tr>
<tr>
<td>• Upper Limb Sensations*</td>
<td>1.2%</td>
<td>1.4%</td>
<td>2.5%</td>
<td>3.6%</td>
</tr>
<tr>
<td>• Palpitations</td>
<td>0.6%</td>
<td>0.3%</td>
<td>1.0%</td>
<td>1.1%</td>
</tr>
<tr>
<td>Neurological</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Head/Face Sensations*</td>
<td>1.3%</td>
<td>2.3%</td>
<td>2.5%</td>
<td>4.7%</td>
</tr>
<tr>
<td>• Dizziness</td>
<td>2.5%</td>
<td>3.1%</td>
<td>3.3%</td>
<td>6.2%</td>
</tr>
<tr>
<td>• Headache</td>
<td>3.3%</td>
<td>4.0%</td>
<td>2.2%</td>
<td>3.3%</td>
</tr>
<tr>
<td>• Vertigo</td>
<td>0.6%</td>
<td>1.1%</td>
<td>1.1%</td>
<td>1.0%</td>
</tr>
<tr>
<td>• Drowsiness</td>
<td>1.6%</td>
<td>1.1%</td>
<td>1.2%</td>
<td>2.1%</td>
</tr>
<tr>
<td>• Tremor</td>
<td>0.4%</td>
<td>0.9%</td>
<td>0.4%</td>
<td>1.1%</td>
</tr>
<tr>
<td>Gastrointestinal</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Nausea</td>
<td>5.8%</td>
<td>2.8%</td>
<td>4.4%</td>
<td>11.0%</td>
</tr>
<tr>
<td>• Hyposalivation</td>
<td>1.2%</td>
<td>1.4%</td>
<td>1.1%</td>
<td>1.2%</td>
</tr>
<tr>
<td>• Vomiting</td>
<td>2.9%</td>
<td>4.3%</td>
<td>1.1%</td>
<td>4.4%</td>
</tr>
<tr>
<td>• Gastrointestinal Discomfort &amp; Pain</td>
<td>1.4%</td>
<td>1.1%</td>
<td>0.8%</td>
<td>2.0%</td>
</tr>
<tr>
<td>• Abdominal Discomfort &amp; Pain</td>
<td>0.3%</td>
<td>NR</td>
<td>0.4%</td>
<td>1.2%</td>
</tr>
<tr>
<td>• Diarrhea</td>
<td>0.9%</td>
<td>0.3%</td>
<td>0.6%</td>
<td>1.1%</td>
</tr>
<tr>
<td>Musculoskeletal</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Musculoskeletal Pain</td>
<td>0.7%</td>
<td>2.3%</td>
<td>0.4%</td>
<td>1.4%</td>
</tr>
<tr>
<td>• Muscle Pain</td>
<td>0.3%</td>
<td>0.9%</td>
<td>0.1%</td>
<td>1.0%</td>
</tr>
<tr>
<td>• Muscle Atrophy Weakness &amp; Tiredness</td>
<td>NR</td>
<td>0.6%</td>
<td>0.4%</td>
<td>1.4%</td>
</tr>
<tr>
<td>Ear, Nose &amp; Throat</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Infections</td>
<td>0.6%</td>
<td>0.6%</td>
<td>1.1%</td>
<td>1.4%</td>
</tr>
<tr>
<td>• Nasal Signs &amp; Symptoms</td>
<td>0.7%</td>
<td>1.4%</td>
<td>0.8%</td>
<td>1.0%</td>
</tr>
<tr>
<td>• Throat &amp; Tonsil Symptoms</td>
<td>0.6%</td>
<td>NR</td>
<td>0.4%</td>
<td>2.3%</td>
</tr>
<tr>
<td>Respiratory</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Viral Infection</td>
<td>0.3%</td>
<td>1.1%</td>
<td>0.1%</td>
<td>1.0%</td>
</tr>
<tr>
<td>Non-Site Specific</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Limb Sensations*</td>
<td>0.4%</td>
<td>1.1%</td>
<td>0.4%</td>
<td>1.5%</td>
</tr>
<tr>
<td>• Sensations* (body region unspecified)</td>
<td>4.5%</td>
<td>5.7%</td>
<td>8.0%</td>
<td>9.0%</td>
</tr>
<tr>
<td>• Malaise/Fatigue</td>
<td>5.1%</td>
<td>3.7%</td>
<td>2.6%</td>
<td>9.5%</td>
</tr>
<tr>
<td>• Sweating</td>
<td>0.4%</td>
<td>0.6%</td>
<td>0.6%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>

* The term “sensations” encompasses adverse events described as pain & discomfort, pressure, heaviness, constriction, tightness, heat/burning or cold sensation, paresthesia, hypoesthesia, numbness, flushing and strange sensations.

** Includes patients receiving up to 3 doses of 100 mg.

NR = Not Reported
Table 3  Treatment-Emergent Adverse Events in Subcutaneous Placebo-Controlled Clinical Trials Reported by at Least 1% of Patients with Migraine

<table>
<thead>
<tr>
<th></th>
<th>Placebo</th>
<th>IMITREX® 6 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of Patients</td>
<td>615</td>
<td>1432</td>
</tr>
<tr>
<td>Number of Migrane Attacks Treated</td>
<td>742</td>
<td>2540</td>
</tr>
<tr>
<td>Symptoms of Potentially Cardiac Origin</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Chest Sensations*</td>
<td>1.6%</td>
<td>5.7%</td>
</tr>
<tr>
<td>• Neck/Throat/Jaw Sensations*</td>
<td>1.3%</td>
<td>12.0%</td>
</tr>
<tr>
<td>• Upper Limb Sensations*</td>
<td>2.0%</td>
<td>6.8%</td>
</tr>
<tr>
<td>Neurological</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Head/Face Sensations*</td>
<td>3.7%</td>
<td>16.6%</td>
</tr>
<tr>
<td>• Dizziness</td>
<td>3.7%</td>
<td>7.9%</td>
</tr>
<tr>
<td>• Headache</td>
<td>0.7%</td>
<td>3.4%</td>
</tr>
<tr>
<td>• Drowsiness</td>
<td>1.8%</td>
<td>2.9%</td>
</tr>
<tr>
<td>Gastrointestinal</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Nausea</td>
<td>5.9%</td>
<td>9.4%</td>
</tr>
<tr>
<td>• Hyposalivation</td>
<td>2.8%</td>
<td>3.3%</td>
</tr>
<tr>
<td>Musculoskeletal</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Muscle Atrophy Weakness &amp; Tiredness</td>
<td>NR</td>
<td>1.7%</td>
</tr>
<tr>
<td>Ear / Nose and Throat</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Throat &amp; Tonsil Symptoms</td>
<td>0.3%</td>
<td>1.0%</td>
</tr>
<tr>
<td>Respiratory</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Breathing Disorders</td>
<td>0.8%</td>
<td>1.3%</td>
</tr>
<tr>
<td>Non-Site Specific</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Sensations* (body region unspecified)</td>
<td>15.9%</td>
<td>39.0%</td>
</tr>
<tr>
<td>• Injection Site Reactions**</td>
<td>10.4%</td>
<td>24.7%</td>
</tr>
<tr>
<td>• Limb Sensations*</td>
<td>1.5%</td>
<td>6.0%</td>
</tr>
<tr>
<td>• Malaise/Fatigue</td>
<td>2.3%</td>
<td>4.7%</td>
</tr>
<tr>
<td>• Sweating</td>
<td>1.1%</td>
<td>1.7%</td>
</tr>
<tr>
<td>• Trunk Symptoms*</td>
<td>0.5%</td>
<td>1.4%</td>
</tr>
</tbody>
</table>

* The term “sensations” encompasses adverse events described as pain & discomfort, pressure, heaviness, constriction, tightness, heat/burning or cold sensation, paresthesia, hypoesthesia, numbness, flushing and strange sensations. NR = Not Reported
** Includes transient injection site pain, stinging/burning, swelling, erythema, bruising and bleeding.
Table 4  Treatment-Emergent Adverse Events in Intranasal Placebo-Controlled Clinical Trials Reported by at Least 1% of Patients with Migraine

<table>
<thead>
<tr>
<th></th>
<th>Placebo</th>
<th>IMITREX® 5 mg</th>
<th>IMITREX® 10 mg</th>
<th>IMITREX® 20 mg**</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of Patients</td>
<td>741</td>
<td>496</td>
<td>1007</td>
<td>1638</td>
</tr>
<tr>
<td>Number of Migraine Attacks Treated</td>
<td>1047</td>
<td>933</td>
<td>1434</td>
<td>2070</td>
</tr>
<tr>
<td>Symptoms of Potentially Cardiac Origin</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Chest Sensations*</td>
<td>0.3%</td>
<td>1.0%</td>
<td>0.7%</td>
<td>0.6%</td>
</tr>
<tr>
<td>• Neck/Throat/Jaw Sensations*</td>
<td>1.2%</td>
<td>0.6%</td>
<td>1.6%</td>
<td>2.3%</td>
</tr>
<tr>
<td>Neurological</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Head/Face Sensations*</td>
<td>0.8%</td>
<td>1.4%</td>
<td>2.4%</td>
<td>2.4%</td>
</tr>
<tr>
<td>• Dizziness</td>
<td>1.2%</td>
<td>1.6%</td>
<td>1.5%</td>
<td>1.2%</td>
</tr>
<tr>
<td>• Headache</td>
<td>0.7%</td>
<td>1.4%</td>
<td>0.9%</td>
<td>0.8%</td>
</tr>
<tr>
<td>• Migraine</td>
<td>2.6%</td>
<td>3.2%</td>
<td>2.4%</td>
<td>1.8%</td>
</tr>
<tr>
<td>Gastrointestinal</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Nausea</td>
<td>10.4%</td>
<td>14.3%</td>
<td>9.6%</td>
<td>8.3%</td>
</tr>
<tr>
<td>• Vomiting</td>
<td>7.6%</td>
<td>11.1%</td>
<td>9.6%</td>
<td>6.8%</td>
</tr>
<tr>
<td>Ear, Nose &amp; Throat</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Sensitivity to Noise</td>
<td>3.1%</td>
<td>4.4%</td>
<td>2.5%</td>
<td>1.5%</td>
</tr>
<tr>
<td>• Nasal Signs &amp; Symptoms</td>
<td>1.3%</td>
<td>3.0%</td>
<td>1.6%</td>
<td>1.8%</td>
</tr>
<tr>
<td>• Infections</td>
<td>0.9%</td>
<td>1.8%</td>
<td>1.3%</td>
<td>0.5%</td>
</tr>
<tr>
<td>• Upper Respiratory Inflammation</td>
<td>0.5%</td>
<td>1.0%</td>
<td>0.6%</td>
<td>0.7%</td>
</tr>
<tr>
<td>• Throat &amp; Tonsil Symptoms</td>
<td>0.8%</td>
<td>0.2%</td>
<td>1.0%</td>
<td>0.7%</td>
</tr>
<tr>
<td>Non-Site Specific</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Sensations* (body region unspecified)</td>
<td>1.8%</td>
<td>2.4%</td>
<td>2.7%</td>
<td>2.4%</td>
</tr>
<tr>
<td>• Malaise/Fatigue</td>
<td>1.3%</td>
<td>1.8%</td>
<td>1.3%</td>
<td>0.8%</td>
</tr>
<tr>
<td>• Descriptions of odour or taste</td>
<td>1.8%</td>
<td>15.3%</td>
<td>20.2%</td>
<td>20.8%</td>
</tr>
</tbody>
</table>

* The term “sensations” encompasses adverse events described as pain & discomfort, pressure, heaviness, constriction, tightness, heat/burning or cold sensation, paresthesia, hypoesthesia, numbness, flushing and strange sensations.

** Includes patients receiving up to 3 doses of 20 mg.

IMITREX® is generally well tolerated. Most of the events were transient in nature and resolved within 45 minutes of subcutaneous administration and within 2 hours of oral or intranasal administration.

Of the 3630 patients treated with IMITREX® Nasal Spray in clinical trials, there was one report of a coronary vasospasm related to IMITREX® administration.

Other Events Observed During Clinical Trials
Minor disturbances of liver function tests have occasionally been observed with sumatriptan treatment. There is no evidence that clinically significant abnormalities occurred more frequently with sumatriptan than with placebo.

Dyspnea has commonly been observed following sumatriptan treatment.

Post-Market Adverse Drug Reactions
The following section enumerates potentially important adverse events that have occurred in clinical practice and that have been reported spontaneously to various surveillance systems. The events enumerated represent reports arising from both domestic and nondomestic use of sumatriptan. These events do not include those already listed in the ADVERSE REACTIONS section above. Because the reports cite events reported...
spontaneously from worldwide postmarketing experience, the frequency of such events and the role of sumatriptan in their causation cannot be reliably determined.

**Cardiac Disorders:** Bradycardia, tachycardia, palpitations, cardiac arrhythmias, transient ischaemic ECG changes, coronary artery vasospasm, angina, myocardial infarction (see CONTRAINDICATIONS, and WARNINGS and PRECAUTIONS).

**Ophthalmologic Disorders:** Patients treated with IMITREX® rarely exhibit visual disorders like flickering and diplopia. Additionally, cases of reduced vision have been observed. Very rarely, both transient and permanent loss of vision have occurred. These occurrences have included reports of retinal vascular occlusion, ocular venous thrombosis, vasospasm of the eye and ischemic optic neuropathy. Visual disorders may also occur during a migraine attack itself.

**Gastrointestinal Disorders:** Colonic ischemia (see WARNINGS and PRECAUTIONS, Cardiovascular, Other Vasospasm Related Events).

**Immune System Disorders:** Hypersensitivity reactions ranging from cutaneous hypersensitivity to anaphylaxis (see WARNINGS and PRECAUTIONS, Immune).

**Nervous System Disorders:** Seizures, although some have occurred in patients with either a history of seizures or concurrent conditions predisposing to seizures there are also reports in patients where no such predisposing factors are apparent (see WARNINGS and PRECAUTIONS, Neurologic).

There have been very rare reports of dystonia and related extrapyramidal disorders, such as choreoathetoid movement, akathisia, parkinsonism and akinesia following both subcutaneous and oral treatments of IMITREX. Patients with previous history of drug related dystonia and patients taking medications recognised to be associated with movement disorders such as SSRIs, may be at higher risk.

Nystagmus, scotoma.

**Vascular Disorders:** Hypotension, Raynaud’s phenomenon, peripheral vascular ischemia (see CONTRAINDICATIONS and WARNINGS and PRECAUTIONS, Increases in Blood Pressure; Cardiovascular; and Other Vasospasm Related Events).

**DRUG INTERACTIONS**

**Drug - Drug Interactions**
Single-dose pharmacokinetic drug interaction studies have not shown evidence of interactions with propranolol, flunarizine, pizotifen or alcohol. Multiple-dose interaction studies have not been performed. The pharmacokinetics of sumatriptan nasal spray were
unaltered when preceded by a single clinical dose of the nasal decongestant xylometazoline (Otrivin®).

**Ergot-Containing Drugs:** Ergot-containing drugs have been reported to cause prolonged vasospastic reactions. Because there is a theoretical basis for these effects being additive, ergot-containing or ergot-type medications (like dihydroergotamine or methysergide) are contraindicated within 24 hours of IMITREX DF® or IMITREX® administration (see CONTRAINDICATIONS).

**MAO Inhibitors:** In studies conducted in a limited number of patients, MAO inhibitors reduce sumatriptan clearance, significantly increasing systemic exposure. Therefore, the use of IMITREX DF® or IMITREX® in patients receiving MAO inhibitors is contraindicated (see CONTRAINDICATIONS and ACTION AND CLINICAL PHARMACOLOGY).

**Selective Serotonin Reuptake Inhibitors (SSRIs)/Serotonin Norepinephrine Reuptake Inhibitors (SNRIs):** Cases of life-threatening serotonin syndrome have been reported during combined use of selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs) and triptans (see WARNINGS AND PRECAUTIONS).

**Other 5-HT₁ agonists:** The administration of IMITREX DF® or IMITREX® with other 5-HT₁ agonists has not been evaluated in migraine patients. As an increased risk of coronary vasospasm is a theoretical possibility with coadministration of 5-HT₁ agonists, use of these drugs within 24 hours of each other is contraindicated.

**Drug - Laboratory Interactions**
IMITREX DF® and IMITREX® are not known to interfere with commonly employed clinical laboratory tests.

**DOSAGE AND ADMINISTRATION**

**Dosing Considerations**

**Adults:**
IMITREX DF® and IMITREX® are indicated for the acute treatment of migraine headache with or without aura. Sumatriptan should not be used prophylactically. Sumatriptan may be given orally, subcutaneously or as a nasal spray. The safety of treating an average of more than four headaches in a 30-day period has not been established. The recommended dose of IMITREX DF® and IMITREX® should not be exceeded.

---

2 Trademark Ciba Self Medication
In selecting the appropriate formulation for individual patients, consideration should be given to the patient’s preference for formulation and the patient’s requirement for rapid onset of relief. Significant relief begins about 10-15 minutes following subcutaneous injection, 15 minutes following intranasal administration and 30 minutes following oral administration.

In addition to relieving the pain of migraine, sumatriptan (all formulations) has also been shown to be effective in relieving associated symptoms of migraine (nausea, vomiting, phonophobia, photophobia). Sumatriptan is equally effective when administered at any stage of a migraine attack. Long term (12-24 months) clinical studies with maximum recommended doses of sumatriptan indicate that there is no evidence of the development of tachyphylaxis, or medication-induced (rebound) headache.

**Geriatrics:** No differences have been observed between the pharmacokinetic parameters in healthy elderly volunteers compared with younger volunteers (less than 65 years old).

**Pediatrics (patients under 18 years of age):** The safety and efficacy of IMITREX DF® or IMITREX® in pediatrics has not been established and its use in this age group is not recommended. (See WARNINGS and PRECAUTIONS, Special populations).

**Recommended Dose and Dosage Adjustment**

**Tablets**
The optimal dose is a single 50 mg tablet. However, depending on individual patient’s needs and response to treatment, some patients may require 100 mg. The maximum recommended single dose is 100 mg. The recommended dose should not be exceeded.

Clinical trials have shown that approximately 50 - 75% of patients have headache relief within two hours after oral dosing with 100 mg, and that a further 15 - 25% have headache relief by 4 hours. Comparator studies have shown similar efficacy rates with the 50 mg and 100 mg tablets.

If the migraine headache returns, or if a patient has a partial response to the initial dose, the dose may be repeated after 2 hours. Not more than 200 mg should be taken in any 24-hour period.

If a patient does not respond to the first dose of IMITREX DF® Tablets, a second dose should not be taken for the same attack, as it is unlikely to be of clinical benefit. IMITREX D® may be taken to treat subsequent migraine attacks.

**Injection**
IMITREX® Injection should be injected subcutaneously (on the outside of the thigh or in the upper arm) using an autoinjector.

The recommended adult dose of sumatriptan is a single 6 mg subcutaneous injection. The recommended dose should not be exceeded.
Clinical trials have shown that approximately 70-72% of patients have headache relief within one hour after a single subcutaneous injection. This number increases to 82% by 2 hours.

If the migraine headache returns, or if a patient has a partial response to the initial dose, the dose may be repeated after 1 hour. Not more than 12 mg (two 6 mg injections) should be taken in any 24-hour period.

If a patient does not respond to the first dose of IMITREX® Injection, a second dose should not be taken for the same attack, as it is unlikely to be of clinical benefit. IMITREX® may be taken for subsequent attacks.

Administration during migraine aura prior to other symptoms occurring may not prevent the development of a headache.

**Nasal Spray**
The minimal effective single adult dose of sumatriptan nasal spray is 5 mg. The maximum recommended single dose is 20 mg. The recommended dose should not be exceeded.

If the migraine headache returns, or if a patient has a partial response to the initial dose, the dose may be repeated after 2 hours. Not more than 40 mg should be taken in any 24-hour period.

As shown in Table 8 (see CLINICAL TRIALS), optimal rates of headache relief were seen with the 20 mg dose. Single doses above 20 mg should not be used due to limited safety data and lack of increased efficacy relative to the 20 mg single dose.

Within the range of 5-20 mg, an increase in dose was not associated with any significant increase in the incidence or severity of adverse events other than taste disturbance (see ADVERSE REACTIONS).

**Special Populations**

**Adults with Mild to Moderate Hepatic Impairment**

**Tablets and Nasal Spray**
Oral and intranasal sumatriptan are not recommended in patients with mild or moderate hepatic impairment (Child Pugh grade A or B) (see WARNINGS AND PRECAUTIONS, Special Populations, Hepatic Impairment).

**Injection**
The pharmacokinetic parameters of 6 mg subcutaneous sumatriptan do not differ statistically between normal volunteers and moderately hepatically impaired subjects (see WARNINGS AND PRECAUTIONS, Special Populations, Hepatic Impairment). No dosage adjustment is necessary for patients with mild to moderate hepatic impairment.
Adults with Severe Hepatic Impairment

Tablets, Nasal Spray and Injection
All formulations of sumatriptan are contraindicated in patients with severe hepatic impairment (see CONTRAINDICATIONS).

Administration

Tablets
The tablet should be swallowed whole with water, not crushed, chewed or split.

Injection
Patients should be advised to read the patient instruction leaflet regarding the safe disposal of syringes and needles.

Nasal Spray
The nasal spray should be administered into one nostril only. The device is a ready-to-use single-dose unit and must not be primed before administration. Patients should be advised to read the patient instruction leaflet regarding the use of the nasal spray device before administration.

OVERDOSAGE

There have been some reports of overdosage with IMITREX®. Patients have received single injections of up to 12 mg subcutaneously without significant adverse effects. Doses up to 16 mg subcutaneously and up to 400 mg orally were not associated with side effects other than those mentioned. The highest dose of IMITREX® Nasal Spray administered without significant adverse effects was 20 mg given three times daily for 4 days.

If overdosage with sumatriptan occurs, the patient should be monitored and standard supportive treatment applied as required. Toxicokinetic data are not available.

The effect of hemodialysis or peritoneal dialysis on the serum concentration of sumatriptan is unknown.

For management of a suspected drug overdose, contact your regional Poison Control Centre.
ACTION AND CLINICAL PHARMACOLOGY

Mechanism of Action
IMITREX DF® and IMITREX® have been shown to be effective in relieving migraine headache. Sumatriptan is an agonist for a vascular 5-hydroxytryptamine1D (5-HT1D) receptor subtype (a member of the 5-HT1 family), and has only weak affinity for 5-HT1A receptors and no significant activity (as measured using standard radioligand binding assays) or pharmacological activity at 5-HT2, 5-HT3, 5-HT4, 5-HT5A, or 5-HT7 receptor subtypes, or at alpha1-, alpha2-, or beta-adrenergic; dopamine1 or dopamine2; muscarinic; or benzodiazepine receptors.

The therapeutic activity of IMITREX DF® and IMITREX® in migraine is generally attributed to its agonist activity at 5-HT1B/5-HT1D receptors. Two current theories have been proposed to explain the efficacy of 5-HT1 receptor agonists in migraine. One theory suggests that activation of 5-HT1 receptors located on intracranial blood vessels, including those on the arteriovenous anastomoses, leads to vasoconstriction, which is believed to be correlated with the relief of migraine headache. The other hypothesis suggests that activation of 5-HT1 receptors on perivascular fibres of the trigeminal system results in the inhibition of pro-inflammatory neuropeptide release. These theories are not mutually exclusive.

Experimental data from animal studies show that sumatriptan also activates 5-HT1 receptors on peripheral terminals of the trigeminal nerve, which innervates cranial blood vessels. This causes the inhibition of neuropeptide release. It is thought that such an action may contribute to the anti-migraine action of sumatriptan in humans.

Cardiovascular Effects
In vitro studies in human isolated epicardial coronary arteries suggest that the predominant contractile effect of 5-HT is mediated via 5-HT2 receptors. However, 5-HT1 receptors also contribute to some degree to the contractile effect seen. Transient increases in systolic and diastolic blood pressure (up to 20 mmHg) of rapid onset (within minutes), have occurred after intravenous administration of up to 64 μg/kg (3.2 mg for 50 kg subject) to healthy volunteers. These changes were not dose related and returned to normal within 10-15 minutes. Following oral administration of 200 mg or intranasal administration of 40 mg, however, mean peak increases in blood pressure were smaller and of slower onset than after intravenous or subcutaneous administration.

Pharmacodynamics
Significant relief begins about 10-15 minutes following subcutaneous injection, 15 minutes following intranasal administration and 30 minutes following oral administration.
Pharmacokinetics

Pharmacokinetic parameters following subcutaneous, oral or intranasal administration are shown in Table 5.

Inter-patient and intra-patient variability was noted in most pharmacokinetic parameters assessed.

Table 5  Summary of Pharmacokinetic Parameters

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Subcutaneous</th>
<th>Oral</th>
<th>Intranasal</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bioavailability</td>
<td>96%</td>
<td>14%</td>
<td>16%</td>
</tr>
<tr>
<td>Cmax (ng/mL)</td>
<td>6 mg: 72 ng/mL</td>
<td>100 mg: 50-60 ng/mL</td>
<td>5 mg: 4.7 ng/mL</td>
</tr>
<tr>
<td></td>
<td>25 mg: 18 ng/mL</td>
<td></td>
<td>10 mg: 8.5 ng/mL</td>
</tr>
<tr>
<td></td>
<td>5 mg: 4.7 ng/mL</td>
<td>20 mg: 14.4 ng/mL</td>
<td></td>
</tr>
<tr>
<td>Tmax</td>
<td>6 mg: 15min</td>
<td>100 mg: 0.5-5 hr*</td>
<td>1-1.5 hr</td>
</tr>
<tr>
<td>T1/2</td>
<td>2 hr (1.7-2.3 hr)</td>
<td>2 hr (1.9-2.2 hr)</td>
<td>2 hr (1.3-5.4 hr)</td>
</tr>
<tr>
<td>Protein Binding</td>
<td>14-21%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Volume of Distribution</td>
<td>170 L</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total Plasma Clearance</td>
<td>1160 mL/min</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Renal Plasma Clearance</td>
<td>260 mL/min</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* 70% to 80% of Cmax values were attained within 30-45 minutes of dosing.

Absorption/Metabolism: Sumatriptan is rapidly absorbed after oral, subcutaneous and intranasal administration. The low oral and intranasal bioavailability is primarily due to metabolism (hepatic and pre-systemic) and partly due to incomplete absorption. The oral absorption of sumatriptan is not significantly affected either during migraine attacks or by food.

In vitro studies with human microsomes suggest that sumatriptan is metabolized by monoamine oxidase (MAO), predominantly the A isoenzyme. In studies conducted in a limited number of patients, MAO inhibitors reduce sumatriptan clearance, significantly increasing systemic exposure.

Excretion: Non-renal clearance of sumatriptan accounts for about 80% of the total clearance. The major metabolite, the indole acetic acid analogue of sumatriptan, is mainly excreted in the urine where it is present as a free acid (35%) and the glucuronide conjugate (11%). It has no known 5-HT1 or 5-HT2 activity. Minor metabolites have not been identified.

Special Populations and Conditions

Geriatrics: No differences have been observed between the pharmacokinetic parameters in healthy elderly volunteers and those in younger volunteers (less than 65 years old).
STORAGE AND STABILITY

IMITREX DF® Tablets should be stored between 15°C and 30°C.

IMITREX® Injection and Nasal Spray should be stored between 2°C to 30°C and protected from light.

DOSAGE FORMS, COMPOSITION AND PACKAGING

Availability of Dosage Forms

IMITREX DF® Tablets are available as pink 100 mg, or white 50 mg film-coated tablets in blister packs containing 6 tablets.

IMITREX® Injection (6 mg; total volume = 0.5 mL) is available in pre-filled syringes placed in a tamper-evident carrying/disposal case. Two pre-filled syringes plus an IMITREX STATdose Pen™ autoinjector are packed in an IMITREX STATdose System™ autoinjector kit. A refill pack is available containing 2 pre-filled syringes in a carton.

IMITREX® Injection is also available to physicians or hospitals in a single-dose vial (6 mg; total volume = 0.5 mL). There are 5 vials per carton.

IMITREX® Nasal Spray 5 mg and 20 mg are each supplied in boxes of 2 nasal spray devices (1 X 2 devices). Each unit dose spray supplies 5 and 20 mg, respectively.

Composition

IMITREX DF® Tablets contain 100 mg, or 50 mg sumatriptan (base) as the succinate salt. IMITREX DF® Tablets also contain croscarmellose sodium, iron oxide red (100 mg only), dibasic calcium phosphate anhydrous, sodium bicarbonate, magnesium stearate, methylhydroxypropyl cellulose, microcrystalline cellulose, titanium dioxide, and triacetin.

IMITREX® Injection contains 6 mg sumatriptan (base) as the succinate salt in an isotonic sodium chloride solution containing water for injection.

IMITREX® Nasal Spray contains 5 mg, or 20 mg of sumatriptan base (as the hemisulphate salt formed in situ) in an aqueous buffered solution containing anhydrous dibasic sodium phosphate, monobasic potassium phosphate, purified water, sodium hydroxide and sulphuric acid.
PART II: SCIENTIFIC INFORMATION

PHARMACEUTICAL INFORMATION

Drug Substance

*Tablet/Injection*

Proper name: sumatriptan succinate (USAN, BAN and INN)

Chemical name: 3-[2-(dimethylamino)ethyl]-N-methyl-indole-5-methanesulphonamide succinate (1:1)

Molecular formula: \( \text{C}_{14}\text{H}_{21}\text{N}_{3}\text{O}_{2}\text{S} \cdot \text{C}_{4}\text{H}_{6}\text{O}_{4} \)

Molecular mass: 413.5

Structural formula:

![Structural formula of sumatriptan succinate](image)

Physicochemical properties:

Physical Characteristics: White to off-white powder with a melting point between 164.6°C-165.5°C.

Solubility:
- In water (4°C) = 54 mg/mL
- In water (20°C) = 101 mg/mL
- In saline (0.9% w/v, 4°C) = 62 mg/mL
- In saline (0.9% w/v, 20°C) = 109 mg/mL

pH and pka:
- The pH of a 1% w/v solution of sumatriptan succinate in water is approximately 4.9.
- \( \text{pka}_1 \) (succinic acid) = 4.21, 5.67
- \( \text{pka}_2 \) (3° amine group) = 9.63
- \( \text{pka}_3 \) (sulphonamide group) >12

Partition Coefficient (between n-octanol and water): \( \log P = 1.07 \) at a pH of 10.7
Nasal Spray

Proper name: sumatriptan

Chemical name: 3-[2-(dimethylamino)ethyl]-N-methyl-1H-indole-5-methanesulphonamide

Molecular formula: C\textsubscript{14}H\textsubscript{21}N\textsubscript{3}O\textsubscript{2}S

Molecular mass: 295.4

Structural formula:

\[
\begin{align*}
\text{CH}_3\text{NH}_2\text{SO}_2\text{CH}_2 & \\
\text{CH}_2\text{CH}_2\text{N(CH}_3\text{)_2} & \\
\text{N} & \\
\text{H} & 
\end{align*}
\]

Physicochemical properties:

Physical Characteristics: White to pale yellow powder with a melting point about 176° C.

Solubility: In water (4°C, 20°C) \approx 1 \text{ mg/mL}

pka: pka\textsubscript{1} (3° amine group) = 9.63 
pka\textsubscript{2} (sulphonamide group) > 12

Partition Coefficient: log P = 1.06 (20°C)

CLINICAL TRIALS

Migraine:

Tablets
The efficacy of IMITREX\textsuperscript{®} Tablets for the treatment of migraine was established in four multicentre, randomized, placebo-controlled studies. Patients enrolled and treated in these studies were primarily female (84%), Caucasian (98%) and with a mean age of 40 years (range of 18 to 65 years). Patients were instructed to treat a moderate to severe headache. In Study 2, up to three doses were permitted to treat a single attack within a 24-hour period, non-responders could take a second dose at two hours, while any recurrence of migraine could be treated with a third dose. Studies 1, 3 and 4 were designed to allow for the treatment of up to three attacks.
Headache relief at two hours was statistically significantly greater for all sumatriptan groups when compared to placebo (see Table 6).

Table 6  Percentage of Patients with Headache Relief (0/1)\(^1\) at 2 Hours Post Oral Dose for the Treatment of Migraine

<table>
<thead>
<tr>
<th>Study</th>
<th>Placebo (%)</th>
<th>25 mg (%)</th>
<th>50 mg (%)</th>
<th>100 mg (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study 1</td>
<td>27 (n=212)</td>
<td>-</td>
<td>-</td>
<td>67* (n=313)</td>
</tr>
<tr>
<td>Study 2</td>
<td>19 (n=84)</td>
<td>-</td>
<td>49 (n=331)</td>
<td>50* (n=149)</td>
</tr>
<tr>
<td>Study 3</td>
<td>23 (n=154)</td>
<td>-</td>
<td>49 (n=331)</td>
<td>-</td>
</tr>
<tr>
<td>Study 4</td>
<td>28 (n=98)</td>
<td>47** (n=303)</td>
<td>61* (n=302)</td>
<td>61* (n=298)</td>
</tr>
</tbody>
</table>

\(^1\) Headache relief is defined as a reduction in headache severity from grade 3 or 2 (severe or moderate) to grade 1 or 0 (mild or no pain).
- = Not evaluated
*\(p<0.001\) vs. placebo
**\(p=0.001\) vs. placebo

In Study 4, the 50 mg (\(p=0.002\)) and 100 mg (\(p=0.003\)) groups had significantly more patients experience headache relief compared to the 25 mg group at 2 hours.

For patients with migraine-associated nausea, photophobia and/or phonophobia at baseline, there was a decreased incidence of these symptoms following administration of IMITREX® Tablets compared to placebo.

**Injection**

The efficacy of IMITREX® Injection was established in three controlled clinical trials for the treatment of migraine. Patients enrolled and treated in these studies were predominantly female (88%), Caucasian (93%) and with a mean age of 39 years (range of 18 to 75 years). Patients with headache severity of at least grade 2 that was not improving were selected as subjects. The response of one headache attack was studied over a period of at least 2 hours. Studies 2 and 3 allowed for an optimal second dose after one hour.

Headache relief at one and two hours was statistically significantly greater for IMITREX® Injection when compared to placebo (see Table 7).
Table 7  Percentage of Patients with Headache Relief (grade 0/1)\(^1\) at 1- and 2- Hours Post Subcutaneous Injection for the Treatment of Migraine

<table>
<thead>
<tr>
<th>Study</th>
<th>Placebo† (%)</th>
<th>6 mg‡ (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study 1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-hour</td>
<td>24</td>
<td>73*</td>
</tr>
<tr>
<td>2-hour</td>
<td>21</td>
<td>70*</td>
</tr>
<tr>
<td>(n = 62)</td>
<td></td>
<td>(n=30)</td>
</tr>
<tr>
<td>Study 2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-hour</td>
<td>18</td>
<td>70*</td>
</tr>
<tr>
<td>2-hour</td>
<td>31</td>
<td>81*</td>
</tr>
<tr>
<td>(n=190)</td>
<td></td>
<td>(n=384)</td>
</tr>
<tr>
<td>Study 3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-hour</td>
<td>26</td>
<td>70*</td>
</tr>
<tr>
<td>2-hour</td>
<td>39</td>
<td>82*</td>
</tr>
<tr>
<td>(n=180)</td>
<td></td>
<td>(n=350)</td>
</tr>
</tbody>
</table>

\(^1\) Headache relief is defined as a reduction in headache severity from grade 3 or 2 (severe or moderate) to grade 1 or 0 (mild or no pain)*.

* p < 0.05 versus placebo.

† Includes patients that may have received an additional placebo injection 1 hour after the initial injection.

‡ Includes patients that may have received an additional 6 mg of IMITREX® Injection 1 hour after the initial injection.

For patients with migraine-associated nausea, photophobia and/or phonophobia at baseline, there was a decreased incidence of these symptoms following administration of IMITREX® Injection compared to placebo.

**Nasal Spray**

The efficacy of IMITREX® Nasal Spray was conducted in seven controlled clinical migraine studies, in a total of 3693 patients. Patients were instructed to treat a moderate or severe migraine attack with a single dose of study medication.

Those who experienced relief at 2 hours and received no rescue medication were allowed to administer a second identical dose within 2 and 24 hours, if significant worsening of migraine occurred. In all studies, patients treated a single attack except in Study 5 where patients were allowed to treat as many as three attacks.

The clinical trials revealed the following incidence of headache relief, defined as a decrease in migraine severity from severe or moderate to mild or no pain, within 2 hours after treatment with intranasal sumatriptan at doses of 5, 10 or 20 mg (see Table 8 below).
Table 8  Percentage of Patients with Headache Relief (0/1)\(^1\) at 2 Hours Post Nasal Spray Dose for the Treatment of Migraine

<table>
<thead>
<tr>
<th>Study</th>
<th>Placebo (%)</th>
<th>5 mg (%)</th>
<th>10 mg (%)</th>
<th>20 mg (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(n=40)</td>
<td>(n=42)</td>
<td>(n=39)</td>
<td>(n=40)</td>
</tr>
<tr>
<td>Study 1</td>
<td>35%</td>
<td>67%(^3)</td>
<td>67%(^3)</td>
<td>78%(^3)</td>
</tr>
<tr>
<td>Study 2</td>
<td>42%</td>
<td>45%(^3)</td>
<td>66%(^3)</td>
<td>74%(^4)</td>
</tr>
<tr>
<td>(n=31)</td>
<td>(n=33)</td>
<td>(n=35)</td>
<td>(n=39)</td>
<td></td>
</tr>
<tr>
<td>Study 3</td>
<td>25%</td>
<td>49%(^3)</td>
<td>46%(^3)</td>
<td>64%(^3)</td>
</tr>
<tr>
<td>(n=63)</td>
<td>(n=122)</td>
<td>(n=115)</td>
<td>(n=119)</td>
<td></td>
</tr>
<tr>
<td>Study 4</td>
<td>25%</td>
<td>-</td>
<td>44%(^3)</td>
<td>55%(^3)</td>
</tr>
<tr>
<td>(n=151)</td>
<td>(n=288)</td>
<td>(n=292)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study 5</td>
<td>32%</td>
<td>44%(^3)</td>
<td>54%(^3)</td>
<td>60%(^3)</td>
</tr>
<tr>
<td>(n=198)</td>
<td>(n=297)</td>
<td>(n=293)</td>
<td>(n=288)</td>
<td></td>
</tr>
<tr>
<td>Study 6</td>
<td>35%</td>
<td>-</td>
<td>54%(^3)</td>
<td>63%(^3)</td>
</tr>
<tr>
<td>(n=100)</td>
<td>(n=106)</td>
<td>(n=102)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study 7</td>
<td>29%</td>
<td>-</td>
<td>43%</td>
<td>62%(^3)</td>
</tr>
<tr>
<td>(n=112)</td>
<td>(n=109)</td>
<td>(n=215)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

1 Headache relief was defined as a decrease in headache severity from severe or moderate to mild or none.

2 n=total number of patients who received treatment.

3 \(p \leq 0.05\) versus placebo

4 \(p \leq 0.05\) vs 5 mg - not evaluated

5 \(p \leq 0.05\) versus lower sumatriptan doses

Patients treated with IMITREX® Nasal Spray 20 mg achieved relief of more migraine-associated symptoms and at earlier time points than patients treated with 5 mg and 10 mg doses.

**Menstrually-Associated Migraine:**

**Tablets**

Two multicentre, randomized, placebo-controlled studies evaluated IMITREX® 50 mg and 100 mg Tablets administered during the mild phase of a menstrually-associated migraine attack. A total of 816 subjects with a mean age of 37 (18-65 years of age), with at least a 1-year history of migraine, and a 6-month history of regularly occurring MAM, were enrolled and treated. MAM was defined as any migraine beginning on Day -2, to +4 with day 1 = the first day of flow. Patients were instructed to treat a single mild, moderate or severe headache within one hour of mild pain onset.

A statistically significantly higher proportion of patients following IMITREX® 50 mg and 100 mg achieved pain-free status at 2 hours post-dose compared with placebo in the treatment of menstrually-associated migraine (see Table 9).
Table 9  Percentage of Patients with Complete Headache Pain Relief\(^1\) at 2 Hours Post Oral Dose for the Treatment of Menstrually-Associated Migraine

<table>
<thead>
<tr>
<th>Study</th>
<th>Placebo (%)</th>
<th>50 mg (%)</th>
<th>100 mg (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study 1</td>
<td>22(^*) (n=132)</td>
<td>51(^*) (n=138)</td>
<td>58(^*) (n=133)</td>
</tr>
<tr>
<td>Study 2</td>
<td>29(^*) (n=118)</td>
<td>51(^*) (n=116)</td>
<td>61(^*) (n=115)</td>
</tr>
</tbody>
</table>

Complete Headache Pain Relief is defined as grade 1(mild pain) reduced to grade 0 (no pain).

\(^*\) p<0.001 vs. placebo

For patients with migraine-associated nausea, photophobia and/or phonophobia at baseline, there was a decreased incidence of these symptoms following administration of IMITREX® tablets compared to placebo.

**Injection**

A double-blind, placebo-controlled parallel group study evaluated the efficacy of the 6 mg IMITREX® Injection in the acute treatment of menstrual migraine with optional open follow-up treatment. A total of 226 patients, aged 18 to 50 years, experiencing menstrual migraine (defined as migraine without aura occurring -3 to 5 days relative to the first day of menstruation), for at least 6 months prior to the study, were enrolled and treated. Up to two moderate to severe attacks could be treated.

Headache relief at 2 hours post first dose was achieved for a significantly greater proportion of patients treated with sumatriptan 6 mg subcutaneous injection than with placebo (See Table 10).

Table 10  Percentage of Patients with Complete Headache Pain Relief\(^1\) at 1 and 2 Hours Post Subcutaneous Injection for the Treatment of Menstrually-Associated Migraine

<table>
<thead>
<tr>
<th></th>
<th>Placebo (%)</th>
<th>6 mg (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1-hour</td>
<td>22(^*) (n=88)</td>
<td>71(^*) (n=73)</td>
</tr>
<tr>
<td>2-hour</td>
<td>31(^*) (n=73)</td>
<td>73(^*) (n=73)</td>
</tr>
</tbody>
</table>

Complete Headache Pain Relief is defined as grade 1(mild pain) reduced to grade 0 (no pain).

\(^*\) p<0.001 vs. placebo

For migraine-associated symptoms, the results showed that there were significantly fewer patients experiencing nausea and photophobia and/or phonophobia in the sumatriptan group compared to placebo.
DETAILED PHARMACOLOGY

Animal Pharmacodynamics
The action of sumatriptan has been studied in a range of isolated preparations in vitro, all known to contain different 5-HT receptor subtypes.

In Beagle dog isolated saphenous vein known to contain 5-HT1 receptors, sumatriptan had a mean EC\textsubscript{50} of 302 nM, while 5-HT had an EC\textsubscript{50} of 44nM.

In cat isolated saphenous vein, sumatriptan (concentrations of up to 10 μM) had no activity on 5-HT1 receptors, suggesting that sumatriptan is a highly selective agonist at some, but not all, 5-HT1 receptors. The contrasting action of sumatriptan at these receptor sites in the Beagle dog and cat isolated saphenous veins provides evidence that 5-HT1 receptors are heterogeneous.

Sumatriptan displayed virtually no activity at 5-HT2 receptors mediating contraction of the rabbit isolated aorta (concentrations up to 50 μM) and at 5-HT3 receptors mediating depolarization of the rat isolated vagus nerve (concentrations up to 100 μM).

The selectivity of sumatriptan was further confirmed by studies in dog isolated saphenous vein, and in dog and primate isolated basilar artery. In these assays sumatriptan was resistant to the selective 5-HT\textsubscript{2} and 5-HT\textsubscript{3} receptor antagonists, ketanserin and MDL72222, respectively. Radioligand binding studies provide yet additional support for the high degree of specificity of sumatriptan. Sumatriptan was shown to have a high affinity for some 5-HT\textsubscript{1} binding sites, notably the 5-HT\textsubscript{1D} subtype, and no significant affinity for other neurotransmitter binding sites such as, 5-HT\textsubscript{1A}, 5-HT\textsubscript{1C}, 5-HT\textsubscript{2}, 5-HT\textsubscript{3}, α\textsubscript{1}, α\textsubscript{2}, β\textsubscript{1}, dopamine D\textsubscript{1} and D\textsubscript{2}, muscarinic and benzodiazepine receptors. In the human isolated basilar artery, methiothepin specifically and equally antagonised the contractile effects of both 5-HT and sumatriptan, suggesting that sumatriptan and 5-HT contract this artery by activating the same receptor type. This receptor appears to be identical to the 5-HT\textsubscript{1} receptor which mediates contraction of the dog isolated saphenous vein and cerebral blood vessels in both the dog and primate.

Sumatriptan selectively reduced the extravasation of plasma proteins in the duramater of rats and guinea pigs, in response to trigeminal nerve stimulation.

Although an inhibitory effect on neurotransmitter release from trigeminal nerve endings is implicated, the action of sumatriptan would still predominantly involve a direct vasoconstrictive action on dural blood vessels, which could be expected to inhibit extravasation. In fact, such a vasoconstrictive action during a migraine attack could also increase the threshold for activating perivascular nerve afferents by reducing pressure on edematous pain-sensitive vessels within the cranium.

The major metabolite of sumatriptan in humans and other animal species, GR49336, has no pharmacological activity at 5-HT\textsubscript{1} receptors or other vascular 5-HT receptor subtypes.

\(^3\) molar concentrations required to produce 50% of the maximum response.
Sumatriptan (1-1000 μg/kg, iv) produced a selective long-lasting and dose-dependent decrease in carotid arterial blood flow, in vivo (anaesthetized Beagles), with little or no change in arterial blood pressure. The dose of sumatriptan producing 50% of its maximum vasoconstrictor action was 39 ± 8 μg/kg, iv. Maximal vasoconstrictor responses were achieved with intravenous doses between 300-1000 μg/kg.

The vasoconstrictor action of sumatriptan in the carotid arterial circulation of anaesthetised Beagles is mediated by the activation of 5-HT1 receptors since it was antagonised by methiothepin, a selective 5-HT1 receptor blocker.

Sumatriptan (30-1000 μg/kg, iv) produced a dose-dependent reduction in the proportion of cardiac output passing through arteriovenous anastomoses (AVAs) in anaesthetized cats.

At doses up to 1000 μg/kg iv, sumatriptan had little effect upon vascular resistance in a variety of other vascular beds. In contrast, the administration of ergotamine (30 μg/kg) caused marked increases in vasoconstriction in most vascular beds examined.

Sumatriptan did not modify efferent vagal activity by either a central action or by interference with cholinergic neurotransmission from vagal nerve endings in the myocardium of anaesthetized cats.

It had no antinociceptive effects in rodents, and is, therefore, unlikely that its effectiveness in alleviating migraine headache is due to a generalized analgesic action.

In conscious monkeys, at cumulative doses of up to 1000 μg/kg, there were no significant effects on arterial blood pressure, heart rate, ECG or respiratory rate that could be attributed to the intravenous administration of sumatriptan.

Sumatriptan up to 1 mg/kg had little or no effect upon either pulmonary artery or esophageal pressure in Beagle dogs. There was also little or no effect upon total peripheral resistance, and only a slight increase in cardiac output and stroke volume.

In the rat, sumatriptan (1 and 10 mg/kg, ip) caused a dose-related increase in the rate of gastric emptying, the magnitude of this effect being comparable with that obtained with metoclopramide at doses of 5-20 mg/kg, ip.

Animal Pharmacokinetics
Absorption of radiolabelled drug-related material following single-dose oral administration of sumatriptan was both rapid and extensive in mice, rats, rabbits and dogs. Oral bioavailabilities of 37% in rat (5 mg/kg), 23% in rabbit (5 mg/kg) and 58% in dog (1 mg/kg) indicate that first-pass metabolism is moderate to high in these species. In dogs, this was supported by low metabolic clearance relative to hepatic blood flow. Following intravenous administration, the parent compound was rapidly eliminated from the plasma of mice, rats and rabbits (t½ ≤ 1.2 h) and less rapidly in dogs (t½ = 2.1 h).
Active tubular secretion of sumatriptan occurred in the kidneys of rats and rabbits but not in the dog, where clearance was primarily metabolic.

The repeat-dose pharmacokinetics of sumatriptan in the mouse, rat, rabbit and dog were generally consistent with the single-dose data. Plasma levels attained in these species showed that sumatriptan concentrations were linearly-related to oral doses up to 160 mg/kg in mice, 200 mg/kg in rats (subcutaneous doses up to 25 mg/kg), 400 mg/kg in rabbits and 100 mg/kg in dogs (subcutaneous doses up to 24 mg/kg).

Following intranasal administration to the rat or dog, plasma concentrations of sumatriptan peaked at approximately 30 minutes; in the monkey it peaked at 15 minutes. A second peak was observed in some animals at 90-120 minutes, suggesting absorption of a swallowed portion of the dose.

The maximum concentrations of sumatriptan detected in plasma following oral or subcutaneous administration to dogs were 35- and 75-fold higher, respectively, than were measured in human plasma following standard therapeutic doses.

There was no evidence of accumulation or enzyme inhibition/induction in any of the species studied.

Radioactive drug-related material was widely distributed throughout the body following both oral and intravenous administration of radiolabelled sumatriptan. Transfer into the central nervous system was limited.

Drug-related material was cleared rapidly from all tissues with the exception of the eye in which it appeared to be bound to the melanin in the uveal tract.

The binding of sumatriptan to plasma proteins over the concentration range 10 to 1000 ng/mL was low, 21% or less, in all species studied. Erythrocyte-associated $^{14}$C-GR43175 was reversibly bound.

Placental transfer studies in rat and rabbit showed that in both species the fetuses were exposed to low levels of drug-related material. Sumatriptan and drug-related material were secreted into the milk of lactating rats and were present at higher concentrations than those seen in maternal plasma.

Following oral administration to the rabbit and dog, and intravenous administration to the dog, and intranasal administration to the rat and dog, the indole acetic acid derivative GR49336 was the major metabolite formed.

This metabolite was also a major component in the urine of rats after both oral and intravenous and intranasal administration and in rabbits after intravenous administration, indicating that oxidative deamination is the major metabolic pathway in all animal species studied.
Metabolism of the methylaminosulphonylmethyl side chain resulting in the formation of an N-demethylated derivative of sumatriptan was apparent in the urine of the mouse, rat, and rabbit but not in the dog.

The major route of excretion was via the urine in the mouse, rabbit and dog following oral and intravenous administration and in the rat following intravenous dosing only.

Following oral administration to rats, the major route of excretion of drug-related material was via the feces.

**Human Pharmacodynamics**
Administration of subcutaneous sumatriptan 6 mg twice daily for 5 days to healthy subjects caused slight increases in mean systolic and diastolic blood pressures (6-8 mmHg) while heart rate decreased slightly (1-7 bpm).

Vasopressor effects were also evident following oral administration, with mean peak increases being somewhat smaller and of slower onset than after parenteral administration. A single oral dose of 200 mg sumatriptan caused significant increases in both systolic and diastolic blood pressures (16 mmHg and 5 mmHg, respectively); however, further dosing (200 mg three times daily for a further 7 days) did not cause any additional vasopressor effects.

In hypertensive patients with common or classical migraine, small, transient increases in both systolic and diastolic blood pressure (maximum mean increase: 6/6 mmHg) occurred shortly after subcutaneous doses of 6 mg, but resolved within 60 minutes. A dose-related increase of 14 mmHg in systolic blood pressure was found in elderly patients given 200 mg oral sumatriptan.

Sumatriptan had no effect on cardiac function in migraine patients when given as a 64 μg/kg intravenous infusion. Exercise tests were performed after each infusion showing that sumatriptan had no effect on left ventricular ejection fraction either at rest or after exercise, and no differences were noted between placebo and sumatriptan.

**TOXICOLOGY**

**Acute Toxicity**
Administration of single oral doses of sumatriptan up to 2000 mg/kg in rats and 1200 mg/kg in mice was well tolerated.

Dogs also survived high oral doses of sumatriptan (500 mg/kg).

In subcutaneous studies, a dose of 2 mg/kg to rats was lethal. Dogs received subcutaneous doses of 20 and 100 mg/kg which were non-lethal. The reactions to treatment were similar irrespective of species or route of administration. Apart from
local damage at the injection sites, there were no macroscopic or microscopic changes noted in any tissue (Table 11).

Table 11  Results from Acute Toxicity (LD50) Studies in Mice, Rats and Dogs

<table>
<thead>
<tr>
<th>SPECIES/STRAIN</th>
<th>ROUTE</th>
<th>APPROX. LD50 (mg/kg)</th>
<th>MNLD (mg/kg)</th>
<th>MLD (mg/kg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mouse: CRH</td>
<td>Oral</td>
<td>1500</td>
<td>≥ 1200</td>
<td>&gt; 1200</td>
</tr>
<tr>
<td>Mouse: CRH</td>
<td>Intravenous</td>
<td>&gt; 15, &lt; 20</td>
<td>≥ 15</td>
<td>≤ 20</td>
</tr>
<tr>
<td>Rat: RH</td>
<td>Intravenous</td>
<td>&gt; 40</td>
<td>≥ 20</td>
<td>≤ 32</td>
</tr>
<tr>
<td>Rat: SD</td>
<td>Subcutaneous</td>
<td>1200 (M) 1400 (F)</td>
<td>≥ 500</td>
<td>≤ 1000</td>
</tr>
<tr>
<td>Dog: Beagle</td>
<td>Oral</td>
<td>&gt; 500</td>
<td>≥ 500</td>
<td>&gt; 500</td>
</tr>
<tr>
<td>Dog: Beagle</td>
<td>Subcutaneous</td>
<td>&gt; 100</td>
<td>≥ 100</td>
<td>&gt; 100</td>
</tr>
</tbody>
</table>

Key: MNLD  - Maximum non-lethal dose  
MLD  - Minimum lethal dose  
(M)  - Male  
(F)  - Female

Long Term Studies
Subacute toxicity studies were conducted for periods up to 6 weeks in RH rats. Sumatriptan was given orally (by gavage) at doses up to 500 mg/kg/day and given subcutaneously at doses up to 81 mg/kg/day.

Clinical signs observed following oral administration were generally minor and transient in nature and occurred predominantly at 500 mg/kg/day. These signs included post-dosing erythema, mydriasis, ataxia, salivation, subdued temperament, postural changes and moist eyes.

Reactions were similar in subcutaneous studies in rats receiving doses of sumatriptan up to 81 mg/kg/day. Local irritation at the injection site was accompanied by a marked inflammatory response, local necrosis, hemorrhage, infiltration, granulation tissue formation and local muscle degeneration and repair. These reactions were dose-dependent.

In dogs administered oral sumatriptan (1-100 mg/kg/day) in studies up to 6 weeks, clinical signs observed included head shaking, scratching, salivation, trembling, agitated behaviour, vocalization, mydriasis and vasodilation. These effects were dose-related. The dogs also developed tachycardia lasting for several hours, often followed by bradycardia. No changes in ECG were detected. Subcutaneous administration of sumatriptan (1-16 mg/kg/day) up to 6 weeks in dogs caused injection site reactions similar to the reactions described in rats.
Chronic toxicity studies were carried out for 24 weeks and 72 weeks in rats and 26 and 60 weeks in dogs.

In both the 24-week and 72-week studies in rats receiving sumatriptan doses of 5, 50 and 500 mg/kg/day orally, clinical signs were similar to those seen in previous oral toxicity studies in rats and were mild and transient in nature.

Animals of each sex receiving 50 and 500 mg/kg/day gained weight more rapidly than controls. This was considered to be related to increased food consumption.

Small reductions in cholesterol levels were frequently noted at 500 mg/kg/day. As well, dose-related increases in urine-specific gravity were seen throughout the 72-week study at 500 mg/kg/day. These increases were of no toxicological significance. Cessation of treatment showed good evidence of recovery.

There were no macroscopic or histological treatment-related findings in any of the organs in either study.

A long term repeat-dose subcutaneous toxicity study of 24 weeks’ duration was performed in RH rats receiving sumatriptan at doses of 1, 8 and 64 mg/kg/day.

There was occasional temporary appearance of masses at the injection sites in the animals receiving the highest dose of sumatriptan. Evidence of injection site injury was also apparent in the recovery animals. Rats in this group showed signs of neutrophilia and lymphocytosis.

Injection site reactions in animals in the high-dose group were similar to those reported during previous toxicity studies.

Studies of 26 and 60 weeks at oral doses of 2, 10 and 50 mg/kg/day were performed in Beagle dogs.

A moderate increase in heart rate was observed in the intermediate (10 mg/kg/day) dose group (60 week study) and in the high (50 mg/kg/day) dose group (26 and 60 week studies). The increase lasted for up to 7 hours after dosing and a dose related decrease in heart rate was evident 24 hours after dosing, at 10 and 50 mg/kg/day. There were no changes in rhythm. Animals of either sex receiving 50 mg/kg/day showed slight reductions in body weight gain in both studies.

In the 60-week study, a dose-related incidence of transient changes was noted on the surface of the cornea. However, these changes were not considered to be treatment-related as evidenced by microscopic examination.

Organ weight analyses revealed significantly increased heart weights in all groups of treated females in the 26-week study. There were no treatment-related effects on organ weights in the 60-week study.
A long term repeat-dose subcutaneous study of 24 weeks’ duration was performed in the Beagle dog at doses of 1, 3.5 and 12 mg/kg/day. Injection site reactions included edema, marked hemorrhage, moderate/chronic inflammation and minimal arteritis. Some minimal injection site changes were also seen in treated animals after a 5-week recovery period.

Transient dose-related changes in the precorneal tear film of treated dogs were observed. There was, however, no histological evidence of damage to the cornea or surrounding tissues.

Analysis of hematological parameters revealed a slight lowering of some red cell parameters in the high-dose (12 mg/kg/day) group. No reticulocyte response was evident. Although no effect on total leucocyte count was observed, lymphocyte numbers were generally lower and neutrophils were generally slightly higher at this dose level. The only change observed during the recovery period was a statistically significantly reduced hemoglobin level in the males.

**Carcinogenicity**

The carcinogenic potential of sumatriptan was evaluated in a 78-week oncogenicity study conducted in mice given oral doses of 10, 60 and 160 mg(base)/kg/day. There were two groups (102 mice each) given the vehicle only.

Tumours were found in more than half of the male mice and in less than half of the females across all groups. There was a statistically significant increase in the incidence of non-fatal hemolymphoreticular tumours observed in males at the dose of 60 mg/kg/day group only when compared with controls. Since there was no dose relationship, this increase was considered to be of no toxicological significance. There was no evidence that administration of sumatriptan at any of the dose levels caused any alteration in the incidence of any specific tumours or non-neoplastic lesions.

A 104-week study was conducted in the Sprague-Dawley rat given oral doses of 10, 60 and 360 mg(base)/kg/day. Two control groups of 100 animals each were given vehicle control only.

There was a significant increase in the incidence of non-fatal adrenal medullary tumours (benign and malignant pheochromocytomas) in males given doses of 10 and 60 mg/kg/day and in males dosed at 360 mg/kg/day. A significant increase in the incidence of benign testicular interstitial (Leydig) cell tumours occurred when compared with controls. Adrenal medullary tumours also increased significantly in females dosed at 60 and 360 mg/kg/day. Comparison of both types of tumours with historical control data indicated that the observations were within the expected background range for the species and that long-term exposure to sumatriptan does not induce any treatment-related increases in the incidences of any tumours for the species tested.
Mutagenicity
Sumatriptan produced no detectable or reproducible mutagenic potential above that seen in controls, in studies conducted in vitro with mutant strains of Salmonella typhimurium, Escherichia coli, or Saccharomyces cerevisiae with or without a rat hepatic drug metabolizing enzyme system. In addition, no statistically significant clastogenic effects were seen in vitro using cultured human peripheral lymphocytes at a maximum dose of 1000 μg/mL in the presence of the rat hepatic drug metabolism enzyme system or in vivo in a rat micronucleus test, at a maximum dosage of 1000 mg/kg.

Sumatriptan showed only weak cytotoxic activity at the highest concentration of 5000 μg/mL tested in vitro with V-79 mammalian cells.

Reproduction and Teratology
In organogenesis studies, oral doses of up to 500 mg/kg/day in the rat were without adverse effects upon fetal parameters measured, but an oral dose of 1000 mg/kg/day in the rat proved toxic to both dams and embryos.

Two oral organogenesis studies were conducted in rabbits, one using daily oral doses of 5, 25 or 100 mg/kg/day and the other using 5, 15 or 50 mg/kg/day. Sumatriptan was administered from days 8-20 of pregnancy.

In the first study, there were no adverse effects at the two lower doses. At the highest dose (100 mg/kg), there was a severe decrease in maternal body weight gain indicating that this dose is maternally toxic. A non-significant increase in post-implantation intra-uterine death from 8.3% in the untreated control group to 21.2% in the high-dose (background range in untreated control animals 1.7% - 15.2%) was observed. In addition there was an increased incidence of subtle variations in the position of certain blood vessels emanating from the aortic arch. In the untreated control these were present at 5.5% of fetuses (3 out of 10 litters affected). At the maternally toxic dose of 100 mg/kg, 23.1% of fetuses had these variations (4 out of 5 litters affected). This type of change is commonly found in untreated control animals (historical control incidence 17.5%; proportion of litters affected 44 out of 91), and does not compromise either health or survival.

In the second oral study, the findings were similar to those seen in the first study. There were no adverse effects at the two lower doses. At the highest dose (50 mg/kg), there was a severe decrease in maternal body weight gain. There were also various fetal effects ascribed to maternal toxicity. There was a slight reduction in mean fetal weight (37.7 g in control, 35.3 g at 50 mg/kg); small increases in the incidence of common skeletal variants (control incidence 8.8%; at 50 mg/kg 20.8%; background mean 6.2%; background range 1.3% - 13.3%) and again an increased incidence of positional changes of certain aortic arch blood vessels; (control incidence 12.8%, 3 out of 20 litters affected; at 50 mg/kg 25%, 10 out of 14 litters affected).

Placental transfer studies in pregnant rabbits have shown that sumatriptan can cross the placental barrier in small amounts. After a 5 mg/kg oral dose, 71.2 ng sumatriptan per
gram of fetus was detected. The blood levels at this dose were 172 - 269 ng/mL. At the maternally toxic dose of 50 mg/kg in rabbits, blood levels reached 3180-6750 ng/mL.

Organogenesis studies conducted using intravenous doses of up to 12.5 mg/kg/day in rats revealed fused ribs at a dose of 2.5 mg/kg/day and rudimentary tail and dilatation of the renal pelvis at a dose of 12.5 mg/kg/day. The treatment had no adverse effects on either the dams or the fetuses and the malformations were considered unrelated to treatment since they are known to occur spontaneously in the control groups of the rat strain employed.

Rabbits were also studied using intravenous doses of up to 8.0 mg/kg/day which revealed no teratological response. However, in the first study a statistically significant dose-related increasing trend in prenatal mortality was seen due to apparent maternal toxicity. In the second study, using intravenous doses up to 2.0 mg/kg/day, no maternal toxicity or increased prenatal mortality were observed.

Fertility studies conducted in rats with oral doses of up to 500 mg/kg/day and subcutaneous doses of up to 60 mg/kg/day indicated that there were no adverse effects upon the reproductive performance of the treated, parental generation, or upon the growth and development of two successive untreated generations.

In peri- and postnatal studies conducted in rats given oral doses of up to 1000 mg/kg/day and subcutaneous doses of up to 81 mg/kg/day, no toxicological adverse effects that may have been relevant to the peri- and postnatal development of their offspring were seen. However, oral administration of 1000 mg/kg/day during periods of pregnancy and lactation resulted in a decrease in maternal and fetal body weight.

A comprehensive evaluation of the effects of sumatriptan on reproduction indicates that the compound is devoid of teratogenic potential in the rat. In addition, there were no adverse effects on fertility or postnatal development. In rabbit oral reproduction studies, there were increased incidences of variations in cervico-thoracic blood vessel configuration in the fetuses, but these were only seen at maternally toxic doses in which blood levels were in excess of 50 times those seen after therapeutic doses in humans. A direct association with sumatriptan treatment is considered unlikely but cannot be excluded. The relevance to humans is unknown.

**Local Tolerance**

The subcutaneous and intramuscular administration of 1 mL of a solution of sumatriptan (50 mg/mL) to rabbits produced no overt signs of irritancy and caused only slight necrotic changes in the deepest layers of the subcuticular muscle. While the subcutaneous lesions healed in a rapid and uncomplicated manner, the intramuscular lesions were moderately slow to heal.

At a lower concentration (2.5 mg/mL) no signs of subcutaneous or intramuscular irritancy were apparent.
In inhalation toxicity studies (dog, monkey), no irritants of the nasal passages or respiratory tract tissues were identified after intranasal administration of sumatriptan.

**Skin and Eye Irritancy**
Sumatriptan produced little or no irritant reaction when applied topically to the skin of guinea pigs and was a non-irritant in the rabbit eye.

Sumatriptan was shown to be devoid of detectable skin sensitizing potential in guinea pigs subjected to a 12-day induction period (0.05 mL of a 10% solution, applied epicutaneously) prior to challenge with sumatriptan.

**Dependence Liability**
The physical dependence liability of sumatriptan was assessed in Cynomolgus monkeys at an oral dose of 5 mg/kg, the lowest tolerable dose causing mild to moderate CNS effects.

The behavioural changes observed upon withdrawal of sumatriptan were limited in number, sporadic, unsustained and not observed in all animals. It would appear that sumatriptan does not share with compounds such as opiates and benzodiazepines the ability to cause physical dependence.
REFERENCES


PART III: CONSUMER INFORMATION

**IMITREX DF®**
(sumatriptan succinate tablets)

This leaflet is part III of a three-part "Product Monograph" published when IMITREX DF® Tablets was approved for sale in Canada and is designed specifically for Consumers. Please read this leaflet carefully before you take IMITREX DF® Tablets. This provides a summary of the information available on your medicine. This leaflet will not tell you everything about IMITREX DF® Tablets. Please do not throw away this leaflet until you have finished your medicine. You may need to read it again. Contact your doctor or pharmacist if you have any questions about the drug.

ABOUT THIS MEDICATION

The name of your medicine is IMITREX DF® (sumatriptan succinate) Tablets. They can be obtained only by prescription from your doctor. The decision to use IMITREX DF® Tablets is one that you and your doctor should make jointly, taking into account your individual preferences and medical circumstances. If you have risk factors for heart disease (such as high blood pressure, high cholesterol, obesity, diabetes, smoking, strong family history of heart disease, or you are postmenopausal or a male over 40), you should tell your doctor, who should evaluate you for heart disease in order to determine if IMITREX DF® Tablets are appropriate for you.

What the medication is used for:
IMITREX DF® Tablets are intended to relieve your migraine headache and other associated symptoms of a migraine attack.

IMITREX DF® Tablets should not be used continuously to prevent or reduce the number of attacks you experience. Use IMITREX DF® Tablets only to treat an actual migraine headache attack.

What it does:
Migraine headache is believed to be caused by a widening of the blood vessels in the head. IMITREX DF® narrows these vessels and relieves the symptoms of migraine headache.

When it should not be used:
Do not use IMITREX DF® Tablets if:
• you have a history, or any symptoms or signs of a heart condition
• you have high blood pressure
• you are taking or have recently taken (within 2 weeks) a monoamine oxidase inhibitor (MAOI)
• you are taking or have recently taken (within 24 hours) an ergotamine containing medication or its derivatives, or another triptan used to treat migraine
• you have any degree of liver disease

IMITREX DF® Tablets should not be used for the treatment of other types of headaches that are different from migraine attacks.

What the medicinal ingredient is:
sumatriptan succinate

What the nonmedicinal ingredients are:
croscarmellose sodium, dibasic calcium phosphate anhydrous, iron oxide red (100 mg only), magnesium stearate, methylhydroxypropyl cellulose, microcrystalline cellulose, sodium bicarbonate, titanium dioxide, and triacetin.

There is no gluten, lactose, sulfite or tartazine in IMITREX DF® Tablets.

What dosage forms it comes in:
IMITREX DF® Tablets are available as pink 100 mg or white 50 mg film-coated tablets in blister packs containing 6 tablets.

WARNINGS AND PRECAUTIONS

BEFORE you use IMITREX DF® Tablets talk to your doctor or pharmacist if:
• you are pregnant, think you might be pregnant, you are trying to become pregnant, you are using inadequate contraception, or you are breast feeding
• you have any chest pain, heart disease, shortness of breath, or irregular heartbeats, you have had a heart attack, or you have angina
• you have risk factors for heart disease (such as high blood pressure, high cholesterol, obesity, diabetes, smoking, strong family history of heart disease, or are postmenopausal or a male over 40)
• you have ever had to stop taking this or any other medication because of an allergy or other problems, or you are allergic to sulpho-containing drugs
• you are taking any medications, including migraine medications such as other triptans, 5-HT1 agonists or those containing ergotamine, dihydroergotamine, or methysergide
• you have ever experienced difficulty moving one side of your body when you have a headache
• you have ever had a stroke, transient ischemic attacks (TIAs), or Raynaud’s Syndrome
• you are under 18 years of age
• you are over 65 years of age
• you are taking any medication for depression (lithium, monoamine oxidase inhibitors, selective serotonin reuptake inhibitors (SSRIs), or serotonin noradrenaline reuptake inhibitors (SNRIs)
• you had, or you have any disease of the liver or kidney
• you had, or you have epilepsy or seizures
• this headache is different from your usual migraine attacks

IMITREX DF® Tablets should not be used continuously to prevent or reduce the number of attacks you experience. Use IMITREX DF® Tablets only to treat an actual migraine headache attack.

If you use IMITREX DF® Tablets too often, it may make your headaches worse. If this happens, your doctor may tell you to stop taking IMITREX DF® Tablets.

The Use of IMITREX DF® Tablets During Pregnancy:
Do not use IMITREX DF® Tablets if you are pregnant, think you might be pregnant, are trying to become pregnant, or are not using adequate contraception, unless you have discussed this with your doctor.

INTERACTIONS WITH THIS MEDICATION

Do not use IMITREX DF® Tablets if you are taking or have recently taken a monoamine oxidase inhibitors (MAOI) in the last 2 weeks, or any migraine medications containing ergotamine, ergot derivatives (such as dihydroergotamine, or methysergide), or other triptans used to treat migraine within 24 hours.

You should tell your doctor if you are taking or have recently taken any other medications (prescription, non-prescription or natural/herbal), before you start taking IMITREX DF® Tablets, especially any antidepressants such as selective serotonin reuptake inhibitors (SSRIs) and certain tricyclics.

PROPER USE OF THIS MEDICATION

The label on the container of your medicine or the leaflet inside should tell you how often to take a dose and the amount you should take in each dose. If it does not or you are not sure, ask your doctor or pharmacist. DO NOT take more medicine or take your medicine more often than you are told.

Usual dose:
Adults: Take as directed by your doctor. If the first tablet does not relieve your headache, do not take further doses of sumatriptan for the same attack. You may take pain medication other than ergotamine-containing preparations for further pain relief. IMITREX DF® may be taken for subsequent attacks. IMITREX DF® Tablets can be taken at any time during your migraine headache.

If your symptoms come back, and it has been two hours since your first tablet, you may take a second tablet.

Do not take more than 200 mg in any 24-hour period.

IMITREX DF® Tablets may be taken with or without food. The tablet should be swallowed whole with water. It should not be crushed, chewed or split.

Overdose:
In case of drug overdose, contact a health care practitioner, hospital emergency department or regional Poison Control Centre immediately, even if there are no symptoms.

SIDE EFFECTS AND WHAT TO DO ABOUT THEM

Like all medications, IMITREX DF® Tablets can cause some side effects. You may not experience any of them. For most patients these side effects are likely to be minor and temporary. However, some may be serious. Consult your doctor if you experience these or other side effects.

The most commonly reported side effects of IMITREX DF® Tablets are:
• pain, pressure or tightness in any part of the body, including chest and throat
• sensations of heaviness
• unusual sensations including numbness, tingling, heat/burning or cold
• flushing (redness of the face lasting for a short time)
• feeling sick or vomiting
• dizziness
• drowsiness
• tiredness
• weakness

As drowsiness may occur as a result of using IMITREX DF® Tablets, do not drive or operate machinery until you are sure that you are not drowsy.
Other side effects include:
- unusually slow or fast heartbeats, a feeling of irregular and/or forceful heartbeats
- visual disturbances, usually temporary (scotoma, nystagmus, flickering, diplopia).
- dystonia, (shaking, tremors or uncontrolled movements)
- loss of normal colouration in the fingers and toes.

Tell your doctor of these symptoms at your next visit. Very rarely, some people have reported the following more serious side effects. For information on what to do if you experience these side effects, see the table at the end of this section.

- pain or tightness in the chest or throat
- loss of vision
- shortness of breath; wheeze; chest tightening; swelling of eyelids, face, or lips; or a skin rash, skin lumps
- a seizure or fit
- sudden and/or severe abdominal pain
- persistent purple discolouration of hands or feet

If you feel unwell in any other way or have any symptoms that you do not understand or find distressing, you should contact your doctor immediately.

### SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM

<table>
<thead>
<tr>
<th>Symptom / effect</th>
<th>Talk with your doctor or pharmacist</th>
<th>Seek immediate medical emergency assistance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common Unusual sensations including numbness, tingling, feeling hot or cold; pain, heaviness or pressure in any part of the body including chest and throat.</td>
<td>Only if severe:  ✓  In all cases: ✓</td>
<td></td>
</tr>
<tr>
<td>Very rare Symptoms of a heart attack [chest pain, sweating, shortness of breath].</td>
<td>Only if severe:  ✓  In all cases: ✓</td>
<td></td>
</tr>
<tr>
<td>Very rare Unusually slow or fast heartbeats, or a feeling of irregular and/or forceful heartbeats.</td>
<td>Only if severe:  ✓  In all cases: ✓</td>
<td></td>
</tr>
</tbody>
</table>

This is not a complete list of side effects. For any unexpected effects while taking IMITREX DF Tablets, contact your doctor or pharmacist.

### HOW TO STORE IT

Keep your medicine in a safe place where children cannot reach it. It may be harmful to children.

Keep your tablets in a cool, dry place (15°C to 30°C). If your medication has expired (the expiration date is printed on the treatment pack), throw it away as instructed.

If your doctor decides to stop your treatment, do not keep any leftover medicine unless your doctor tells you to. Throw away your medicine as instructed.

Reminder:
REMEMBER: This medicine is for you. Only a doctor can prescribe it for you. Never give it to someone else. It may harm them even if their symptoms appear to be similar to yours.
REPORTING SUSPECTED SIDE EFFECTS
You can report any suspected adverse reactions associated with the use of health products to the Canada Vigilance Program by one of the following 3 ways:

- Report online at [www.healthcanada.gc.ca/medeffect](http://www.healthcanada.gc.ca/medeffect)
- Call toll-free at 1-866-234-2345
- Complete a Canada Vigilance Reporting Form and:
  - Fax toll-free to 1-866-678-6789, or
  - Mail to: Canada Vigilance Program
    Health Canada
    Postal Locator 0701C
    Ottawa, ON K1A 0K9

Postage paid labels, Canada Vigilance Reporting Form and the adverse reaction reporting guidelines are available on the MedEffect™ Canada Web site at [www.healthcanada.gc.ca/medeffect](http://www.healthcanada.gc.ca/medeffect).

*NOTE: Should you require information related to the management of side effects, contact your health professional. The Canada Vigilance Program does not provide medical advice.*

MORE INFORMATION

This document plus the full product monograph, prepared for health professionals can be found at: [http://www.gsk.ca](http://www.gsk.ca) or by contacting the sponsor,
GlaxoSmithKline Inc.
7333 Mississauga Road
Mississauga, Ontario
L5N 6L4
1-800-387-7374

This leaflet was prepared by GlaxoSmithKline Inc.

Last revised:

©2014 GlaxoSmithKline, All Rights Reserved
® IMITREX DF is a registered trademark, used under license by GlaxoSmithKline Inc.
PART III: CONSUMER INFORMATION

PrIMITREX®
(sumatriptan succinate injection)
Subcutaneous Injection and Autoinjector

This leaflet is part III of a three-part "Product Monograph" published when IMITREX® Injection was approved for sale in Canada and is designed specifically for Consumers. Please read this leaflet carefully before you take IMITREX® Injection. This provides a summary of the information available on your medicine. This leaflet will not tell you everything about IMITREX® Injection. Please do not throw away this leaflet until you have finished your medicine. You may need to read it again. Contact your doctor or pharmacist if you have any questions about the drug.

ABOUT THIS MEDICATION

The name of your medicine is IMITREX® (sumatriptan succinate) Injection. It can be obtained only by prescription from your doctor. The decision to use IMITREX® Injection is one that you and your doctor should make jointly, taking into account your individual preferences and medical circumstances. If you have risk factors for heart disease (such as high blood pressure, high cholesterol, obesity, diabetes, smoking, strong family history of heart disease, or you are postmenopausal or a male over 40), you should tell your doctor, who should evaluate you for heart disease in order to determine if IMITREX® Injection is appropriate for you.

What the medication is used for:
IMITREX® Injection is intended to relieve your migraine headache and other associated symptoms of a migraine attack.

What it does:
Migraine headache is believed to be caused by a widening of the blood vessels in the head. IMITREX® narrows these vessels and relieves the symptoms of migraine headache.

What should not be used:
Do not use IMITREX® Injection if:
• you are allergic to sumatriptan or to any of the ingredients in IMITREX® Injection. (See “What the nonmedicinal ingredients are:”)
• you have a history, or any symptoms or signs of a heart condition
• you have high blood pressure
• you are taking or have recently taken (within 2 weeks) a monoamine oxidase inhibitor (MAOI)
• you are taking or have recently taken (within 24 hours) an ergotamine containing medication or its derivatives, or another triptan used to treat migraine
• you have severe liver disease

IMITREX® Injection should not be used for the treatment of other types of headaches that are different from migraine attacks

IMITREX® Injection should not be given intravenously, but only into the tissues just below the skin (on the outside of the thigh or in the upper arm).

What the medicinal ingredient is:
sumatriptan succinate

What the nonmedicinal ingredients are:
sodium chloride solution

There is no gluten, lactose, sulfite or tartazine in IMITREX® Injection.

What dosage forms it comes in:
IMITREX® Injection (6 mg; total volume = 0.5 mL) is available in pre-filled syringes placed in a tamper-evident carrying/disposal case. Two pre-filled syringes plus an IMITREX STATdose Pen® autoinjector are packed in an IMITREX STATdose System® autoinjector kit. A refill pack is available containing 2 pre-filled syringes in a carton.

WARNINGS AND PRECAUTIONS

BEFORE you use IMITREX® Injection talk to your doctor or pharmacist if:

• you are pregnant, think you might be pregnant, you are trying to become pregnant, you are using inadequate contraception, or you are breast feeding
• you have any chest pain, heart disease, shortness of breath, or irregular heartbeats, you have had a heart attack, or you have angina
• you have risk factors for heart disease (such as high blood pressure, high cholesterol, obesity, diabetes, smoking, strong family history of heart disease, or are you postmenopausal or a male over 40)
• you have ever had to stop taking this or any other medication because of an allergy or other problems, or you are allergic to sulpha-containing drugs
• you are taking any medications, including migraine medications such as other triptans, 5-HT1 agonists or those containing ergotamine, dihydroergotamine, or methysergide
• you have ever experienced difficulty moving one side of your body when you have a headache
• you have ever had a stroke, transient ischemic attacks (TIAs), or Raynaud’s Syndrome
• you are under 18 years of age
• you are over 65 years of age
• you are taking any medication for depression (lithium, monoamine oxidase inhibitors, selective serotonin reuptake inhibitors (SSRIs), or serotonin noradrenaline reuptake inhibitors (SNRIs)
• you had, or you have any disease of the liver or kidney
• you had, or you have epilepsy or seizures
• this headache is different from your usual migraine attacks

IMITREX® Injection should not be used continuously to prevent or reduce the number of attacks you experience. Use IMITREX® Injection only to treat an actual migraine headache attack.

If you use IMITREX® Injection too often, it may make your headaches worse. If this happens, your doctor may tell you to stop using IMITREX® Injection.

The Use of IMITREX® Injection During Pregnancy:
Do not use IMITREX® Injection if you are pregnant, think you might be pregnant, are trying to become pregnant, or are not using adequate contraception, unless you have discussed this with your doctor.

INTERACTIONS WITH THIS MEDICATION

Do not use IMITREX® Injection if you are taking or have recently taken a monoamine oxidase inhibitors (MAOI) in the last 2 weeks, or any migraine medications containing ergotamine, ergot derivatives (such as dihydroergotamine, or methysergide), or other triptans used to treat migraine within 24 hours.

You should tell your doctor if you are taking or have recently taken any other medications (prescription, non-prescription or natural/herbal), before you start taking IMITREX® Injection, especially any antidepressants such as SSRIs and certain tricyclics.

PROPER USE OF THIS MEDICATION

The label on the container of your medicine or the leaflet inside should tell you how often to take a dose and the amount you should take in each dose. If it does not or you are not sure, ask your doctor or pharmacist. DO NOT take more medicine or take your medicine more often than you are told.
Figure 1

How to Load the Cartridge Pack
- Open the lid of the carrying case. The IMITREX STATdose Pen® autoinjector is already in its place (see Figure 2).

Figure 2

- Remove the cartridge pack from its package. DO NOT REMOVE THE TAMPER-EVIDENT SEALS. Push the cartridge pack and smoothly slide the cartridge pack into the carrying case, clicking it down into place (see Figures 3a and 3b).

Figure 3a

Figure 3b

- The cartridge pack is in the right position when the blue buttons show through the holes in the carrying case. Close the lid.

How to Load the IMITREX STATdose Pen® Autoinjector

Do not load the IMITREX STATdose Pen® autoinjector until you are ready to give an injection.

- Open the carrying case.
  Note: Do not use a syringe cartridge if the tamper-evident seal is broken or missing.

- Remove the tamper-evident seal from one container of the cartridge pack. Discard the seal and open the cartridge lid (see Figure 4).

Figure 4

CAUTION: DO NOT TOUCH THE BLUE BUTTON ON TOP OF THE IMITREX STATdose Pen® UNTIL READY TO INJECT.

- Grasp the IMITREX STATdose Pen® by the ridges at the top (see Figure 5). Take it out of the carrying case.

Figure 5

- Note: The spring mechanism in the IMITREX STATdose Pen® is primed and ready for use when you take the IMITREX STATdose Pen® out of the carrying case. If the white plunger rod is sticking out from the lower end of the IMITREX STATdose Pen®, put the IMITREX STATdose Pen® back into the carrying case and press down firmly until you feel it click. Remove from the carrying case.

- To load the syringe cartridge, insert the IMITREX STATdose Pen® into the cartridge pack and turn clockwise until it no longer turns (about half a turn)(see Figure 6).
Grasping the ridges, pull the loaded IMITREX STATdose Pen® straight out. You may feel some resistance; again be careful not to press the blue button (see Figure 7).

The IMITREX STATdose Pen® is now loaded and ready for use.

Do not try to put the loaded IMITREX STATdose Pen® back into the carrying case as this will damage the needle.

Note: A safety feature is provided that prevents accidental firing until you are ready. The device will only work when pressed against the skin and the grey section slides down to the blue section (see Figure 8).

How to Use the IMITREX STATdose Pen® Autoinjector

- Before injecting, identify an area with an adequate fatty tissue layer (for example, on the outside of the thigh or in the upper arm).
- Clean the skin area to be injected.
- To inject, press the loaded IMITREX STATdose Pen® autoinjector against the skin so that the grey section slides down to the blue section. This releases the safety catch.
- While holding the IMITREX STATdose Pen® against the skin, firmly push the blue button. Then hold the IMITREX STATdose Pen® still for at least 5 seconds. If the IMITREX STATdose Pen® is removed from the skin too soon, not all of the medicine will be released (see Figures 9 and 10).

After 5 seconds, carefully remove the IMITREX STATdose Pen®. The needle will be showing. DO NOT TOUCH THE NEEDLE (see Figure 11).

Immediately return the used syringe cartridge into the cartridge pack by pushing the IMITREX STATdose Pen® down into the empty side of the cartridge pack as far as it will go (see Figure 12). Then turn the IMITREX STATdose Pen® counterclockwise about half a turn until the pen is released from the syringe cartridge (see Figure 13).
Figure 12

- Pull the empty IMITREX STATdose Pen® out of the cartridge pack and close the lid over the used syringe cartridge.
  Note: Because the device has now been used, the white plunger rod will stick out from the lower end of the IMITREX STATdose Pen®.

- Put the IMITREX STATdose Pen® back into the carrying case and press down firmly until you feel it click.

- Close the carrying case lid. If the lid does not close, you have not primed the device for next use. Push the pen down until you feel it click, and then close the lid (see Figure 14).

Figure 13

How to Remove the Used Cartridge Pack

- When both doses have been used, the cartridge pack should be removed from the carrying case (see Figure 15).

Figure 15

- Open the carrying case lid.

- Hold the carrying case and press the two blue buttons, which are located on either side of the carrying case, with one hand.

- Gently pull out the cartridge pack with the other hand. When properly inserted, the syringe cartridges are in a disposable, protective case intended to avoid possible needle sticks or misuse of syringes (see Figure 16). Insert a new cartridge pack.

Figure 16

SIDE EFFECTS AND WHAT TO DO ABOUT THEM

Like all medications, IMITREX® Injection can cause some side effects. You may not experience any of them. For most patients these side effects are likely to be minor and temporary. However, some may be serious. Consult your doctor if you experience these or other side effects.

The most commonly reported side effects of IMITREX® Injection are:

- pain, pressure or tightness in any part of the body, including chest and throat
- sensations of heaviness
- unusual sensations including numbness, tingling, heat/burning or cold
- flushing (redness of the face lasting for a short time)
- feeling sick or vomiting
- dizziness

Note: This action primes the spring mechanism in the IMITREX STATdose Pen® for the next use.

- After both syringe cartridges have been used, remove the cartridge pack and discard.

- NEVER ATTEMPT TO REUSE A SYRINGE CARTRIDGE.
drowsiness  
- tiredness  
- weakness  
- redness at the site of injection, but this usually lasts less than an hour

As drowsiness may occur as a result of using IMITREX® Injection, do not drive or operate machinery until you are sure that you are not drowsy.

Other side effects include:
- unusually slow or fast heartbeats, a feeling of irregular and/or forceful heartbeats  
- visual disturbances, usually temporary (scotoma, nystagmus, flickering, diplopia; usually temporary)  
- dystonia (shaking, tremors or uncontrolled movements)  
- loss of normal colouration in the fingers and toes

Tell your doctor of these symptoms at your next visit.

Very rarely, some people have reported the following more serious side effects. For information on what to do if you experience these side effects, see the table at the end of this section.

- pain or tightness in the chest or throat  
- loss of vision  
- shortness of breath; wheeziness; chest tightening; swelling of eyelids, face, or lips; or a skin rash, skin lumps  
- a seizure or fit  
- sudden and/or severe abdominal pain  
- persistent purple discolouration of hands or feet

If you feel unwell in any other way or have any symptoms that you do not understand or find distressing, you should contact your doctor immediately.

| SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM |
|--------------------------------------------------|-----------------|----------------------|
| **Symptom / effect**                              | **Talk with your doctor or pharmacist** | **Seek immediate medical emergency assistance** |
|                                                  | **Only if severe** | **In all cases** |
| Very common                                     | Unusual sensations including numbness, tingling, feeling hot or cold; pain, heaviness or | ✓ | |
| Very rare                                       | Pressure in any part of the body including chest and throat. | | |
| Common                                          | Pain or sensations of tingling, heat or pressure in any part of the body. | ✓ | |
| Very rare                                       | Symptoms of a heart attack [chest pain, sweating, shortness of breath]. | ✓ | |
| Very rare                                       | Unusually slow or fast heartbeats, or a feeling of irregular and/or forceful heartbeats. | ✓ | |
| Very rare                                       | Allergic reactions [shortness of breath, sudden wheeziness, chest tightness, swelling of the eyelids, face or lips, lumpy skin rash or hives] | ✓ | |
| Very rare                                       | Seizures [loss of consciousness with uncontrollable shaking (“fit“)] | ✓ | |
| Very rare                                       | Lower abdominal pain and/or severe rectal bleeding. | ✓ | |
| Very rare                                       | Raynaud’s phenomenon [persistent purple discolouration of hands or feet]. | ✓ | |
### SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM

<table>
<thead>
<tr>
<th>Symptom / effect</th>
<th>Talk with your doctor or pharmacist</th>
<th>Seek immediate medical emergency assistance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Very rare</td>
<td>Loss of vision.</td>
<td>✔</td>
</tr>
</tbody>
</table>

*This is not a complete list of side effects. For any unexpected effects while taking IMITREX® Injection, contact your doctor or pharmacist.*

### HOW TO STORE IT

Keep your medicine in a safe place where children cannot reach it. It may be harmful to children.

Keep your syringes away from heat and light which may spoil them. Always keep your injection in the case provided and store between 2°C and 30°C.

If your medication has expired (the expiration date is printed on the treatment pack), throw it away as instructed. Needles and syringes may be hazardous and should be disposed of safely and hygienically. Do not throw away your IMITREX STATdose Pen® autoinjector.

If your doctor decides to stop your treatment, do not keep any leftover medicine unless your doctor tells you to. Throw away your medicine as instructed.

**Reminder:**

**REMEMBER:** This medicine is for you. Only a doctor can prescribe it for you. Never give it to someone else. It may harm them even if their symptoms appear to be similar to yours.

### REPORTING SUSPECTED SIDE EFFECTS

You can report any suspected adverse reactions associated with the use of health products to the Canada Vigilance Program by one of the following 3 ways:

- Report online at [www.healthcanada.gc.ca/medeffect](http://www.healthcanada.gc.ca/medeffect)
- Call toll-free at 1-866-234-2345
- Complete a Canada Vigilance Reporting Form and:  
  - Fax toll-free to 1-866-678-6789, or  
  - Mail to: Canada Vigilance Program  
    Health Canada  
    Postal Locator 0701C  
    Ottawa, ON K1A 0K9

Postage paid labels, Canada Vigilance Reporting Form and the adverse reaction reporting guidelines are available on the MedEffect™ Canada Web site at [www.healthcanada.gc.ca/medeffect](http://www.healthcanada.gc.ca/medeffect).

**NOTE:** Should you require information related to the management of side effects, contact your health professional. The Canada Vigilance Program does not provide medical advice.

### MORE INFORMATION

This document plus the full product monograph, prepared for health professionals can be found at: [http://www.gsk.ca](http://www.gsk.ca) or by contacting the sponsor, GlaxoSmithKline Inc.

7333 Mississauga Road  
Mississauga, Ontario  
L5N 6L4  
1-800-387-7374

This leaflet was prepared by GlaxoSmithKline Inc.

Last revised:

©2014 GlaxoSmithKline, All Rights Reserved  
*IMITREX, IMITREX STATdose Pen and IMITREX STATdose System are registered trademarks, used under license by GlaxoSmithKline Inc.*
PART III: CONSUMER INFORMATION

PrIMITREX®
(sumatriptan nasal spray)

This leaflet is part III of a three-part "Product Monograph" published when IMITREX® Nasal Spray was approved for sale in Canada and is designed specifically for Consumers. Please read this leaflet carefully before you use IMITREX® Nasal Spray. This provides a summary of the information available on your medicine. This leaflet will not tell you everything about IMITREX® Nasal Spray. Please do not throw away this leaflet until you have finished your medicine. You may need to read it again. Contact your doctor or pharmacist if you have any questions about the drug.

ABOUT THIS MEDICATION

The name of your medicine is IMITREX® (sumatriptan) Nasal Spray. It can be obtained only by prescription from your doctor. The decision to use IMITREX Nasal Spray is one that you and your doctor should make jointly, taking into account your individual preferences and medical circumstances. If you have risk factors for heart disease (such as high blood pressure, high cholesterol, obesity, diabetes, smoking, strong family history of heart disease, or you are postmenopausal or a male over 40), you should tell your doctor, who should evaluate you for heart disease in order to determine if IMITREX Nasal Spray is appropriate for you.

What the medication is used for:
IMITREX® Nasal Spray is intended to relieve your migraine headache and other associated symptoms of a migraine attack.

What it does:
Migraine headache is believed to be caused by a widening of the blood vessels in the head. IMITREX® narrows these vessels and relieves the symptoms of migraine headache.

When it should not be used:
Do not use IMITREX® Nasal Spray if:
• you have high blood pressure
• you are taking or have recently taken (within 2 weeks) a monoamine oxidase inhibitor (MAOI)
• you are taking or have recently taken (within 24 hours) an ergotamine containing medication or its derivatives, or another triptan used to treat migraine
• you have any degree of liver disease

IMITREX® Nasal Spray should not be used for the treatment of other types of headaches that are different from migraine attacks.

What the medicinal ingredient is:
sumatriptan

What the nonmedicinal ingredients are:
anhydrous dibasic sodium phosphate, monobasic potassium phosphate, purified water, sodium hydroxide and sulphuric acid.

There is no gluten, lactose, sulfite or tartazine in IMITREX® Nasal Spray.

What dosage forms it comes in:
IMITREX® Nasal Spray 5 mg and 20 mg are each supplied in boxes of 2 nasal spray devices (1 X 2 devices). Each unit dose spray supplies 5 and 20 mg, respectively.

WARNINGS AND PRECAUTIONS

BEFORE you use IMITREX® Nasal Spray talk to your doctor or pharmacist if:
• you are pregnant, think you might be pregnant, you are trying to become pregnant, you are using inadequate contraception, or you are breast feeding
• you have any chest pain, heart disease, shortness of breath, or irregular heartbeats, you have had a heart attack, or you have angina
• you have risk factors for heart disease (such as high blood pressure, high cholesterol, obesity, diabetes, smoking, strong family history of heart disease, or are you postmenopausal or a male over 40)
• you have ever had to stop taking this or any other medication because of an allergy or other problems, or you are allergic to sulpha-containing drugs
• you are taking any medications, including migraine medications such as other triptans, 5-HT1 agonists or those containing ergotamine, dihydroergotamine, or methysergide
• you have ever experienced difficulty moving one side of your body when you have a headache
• you have ever had a stroke, transient ischemic attacks (TIAs), or Raynaud’s Syndrome
• you are under 18 years of age
• you are over 65 years of age
• you are taking any medication for depression (lithium, monoamine oxidase inhibitors, selective serotonin reuptake inhibitors (SSRIs), or serotonin noradrenaline reuptake inhibitors (SNRIs)
• you had, or you have any disease of the liver or kidney
• you had, or you have epilepsy or seizures
• this headache is different from your usual migraine attacks

IMITREX® Nasal Spray should not be used continuously to prevent or reduce the number of attacks you experience. Use IMITREX® Nasal Spray only to treat an actual migraine headache attack.

If you use IMITREX® Nasal Spray too often, it may make your headaches worse. If this happens, your doctor may tell you to stop using IMITREX® Nasal Spray.

The Use of IMITREX® Nasal Spray During Pregnancy:
Do not use IMITREX® Nasal Spray if you are pregnant, think you might be pregnant, are trying to become pregnant, or are not using adequate contraception, unless you have discussed this with your doctor.

INTERACTIONS WITH THIS MEDICATION

Do not use IMITREX® Nasal Spray if you are taking or have recently taken a monoamine oxidase inhibitors (MAOI) in the last 2 weeks, or any migraine medications containing ergotamine, ergot derivatives (such as dihydroergotamine, or methysergide), or other triptans used to treat migraine within 24 hours.

You should tell your doctor if you are taking or have recently taken any other medications (prescription, non-prescription or natural/herbal), before you start taking IMITREX® Nasal Spray, especially any antidepressants such as SSRIs and certain tricyclics.

PROPER USE OF THIS MEDICATION

The label on the container of your medicine or the leaflet inside should tell you how often to take a dose and the amount you should take in each dose. If it does not or you are not sure, ask your doctor or pharmacist. DO NOT take more medicine or take your medicine more often than you are told.

Usual dose:

NASAL SPRAY:
DO NOT test the spray before using. Unlike other nasal sprays you may have used, IMITREX® Nasal Spray comes ready to use.

Adults: Use 1 spray in 1 nostril ONLY as directed by your doctor. If the first nasal spray does not relieve your headache do not take a further dose of sumatriptan for the same attack. However, you may take pain medication other than ergotamine-containing preparations for further pain relief. Sumatriptan may be taken for subsequent attacks.

IMITREX® Nasal Spray can be taken at any time during your migraine headache.

A second nasal spray can be taken if your symptoms come back provided 2 hours have passed since the last dose. Do not take more than 40 mg in any 24-hour period.

Overdose:

In case of drug overdose, contact a health care practitioner, hospital emergency department or regional Poison Control Centre immediately, even if there are no symptoms.

INSTRUCTIONS FOR USE OF YOUR IMITREX® NASAL SPRAY

The Nasal Spray Pack
• Your IMITREX® Nasal Spray is packed in a box containing the nasal spray devices individually sealed in blisters. Each device contains one dose of IMITREX®.

• Do not open a blister until you are ready to use your medication. Each nasal spray device is sealed in a blister to help keep it clean and safe. If you carry a nasal spray device around out of the blister, or in an open blister, it may not work properly when you need it.

• Keep your IMITREX® Nasal Spray in the box to help protect it from light and damage. If you want to carry only one nasal spray device around with you, you may split the blister pack in two.

• Keep this information leaflet in a safe place. This leaflet tells you how to use your nasal spray device and provides other useful information about your medicine.
The IMITREX® Nasal Spray device consists of the following parts:

- **Nozzle**: This is the part that you put into your nostril. The spray comes out of a tiny hole in the top.

- **Finger-Grip**: This is the part that you hold when you use the device.

- **Blue Plunger**: When you press the plunger the entire dose sprays into your nostril. The Plunger only works once so do not press it until you have inserted the nozzle into your nostril or you will waste the dose.

**How to use IMITREX® Nasal Spray**

Do not remove the nasal spray device from the blister packaging until you are ready to use it.

- Blow your nose if it feels blocked.

- Peel open a blister pack and take out a nasal spray device.

- Hold the nasal spray device gently with your fingers and thumb as shown in the picture. DO NOT press the blue plunger yet.

- Block one nostril by pressing a finger firmly on the side of your nose, and breathe out gently through your mouth.

- Put the nozzle of the nasal spray device into your other nostril, as far as it feels comfortable.

- Hold your head in an upright position, looking straight ahead and close your mouth. Do not tilt your head and do not lie down.

- Start to breathe in gently through your nose and at the same time press the blue plunger firmly with your thumb. This will spray the entire dose into your nostril.

**Note**: The plunger may feel a bit stiff and you may hear it click.

- Keep your head upright, looking straight ahead, and breathe in gently through your nose and out through your mouth for 10-20 seconds. DO NOT BREATHE DEEPLY; this helps the medicine stay in your nose so that it can be absorbed into your body. You can remove the device and your finger from the other side of your nose while you do this.

- Your nose may feel wet inside and you may notice a slight taste after using the spray - this is normal and will soon pass.

- Your nasal spray device is now empty. It should be disposed of safely and hygienically.
SIDE EFFECTS AND WHAT TO DO ABOUT THEM

Like all medications, IMITREX® Nasal Spray can cause some side effects. You may not experience any of them. For most patients these side effects are likely to be minor and temporary. However, some may be serious. Consult your doctor if you experience these or other side effects.

The most commonly reported side effects of IMITREX® Nasal Spray are:
- pain, pressure or tightness in any part of the body, including chest and throat
- sensations of heaviness
- unusual sensations including numbness, tingling, heat/burning or cold
- flushing (redness of the face lasting for a short time)
- feeling sick or vomiting
- dizziness
- drowsiness
- tiredness
- weakness
- a slight taste after using the nasal spray that is normal and will pass soon

As drowsiness may occur as a result of using IMITREX® Nasal Spray, do not drive or operate machinery until you are sure that you are not drowsy.

Other side effects include:
- unusually slow or fast heartbeats, a feeling of irregular and/or forceful heartbeats
- visual disturbances, usually temporary (scotoma, nystagmus, flickering, diplopia; usually temporary).
- dystonia, (shaking, tremors or uncontrolled movements)
- loss of normal colouration in the fingers and toes.

Tell your doctor of these symptoms at your next visit.

Very rarely, some people have reported the following more serious side effects. For information on what to do if you experience these side effects, see the table at the end of this section.

- pain or tightness in the chest or throat
- loss of vision
- shortness of breath; wheeziness; chest tightening; swelling of eyelids, face, or lips; or a skin rash, skin lumps
- a seizure or fit
- sudden and/or severe abdominal pain
- persistent purple discolouration of hands or feet

If you feel unwell in any other way or have any symptoms that you do not understand or find distressing, you should contact your doctor immediately.

### SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM

<table>
<thead>
<tr>
<th>Symptom / effect</th>
<th>Talk with your doctor or pharmacist</th>
<th>Seek immediate medical emergency assistance</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Common</strong></td>
<td>Unusual sensations including numbness, tingling, feeling hot or cold; pain, heaviness or pressure in any part of the body including chest and throat.</td>
<td>✅</td>
</tr>
<tr>
<td><strong>Very rare</strong></td>
<td>Symptoms of a heart attack [chest pain, sweating, shortness of breath].</td>
<td>✅</td>
</tr>
<tr>
<td><strong>Very rare</strong></td>
<td>Unusually slow or fast heartbeats, or a feeling of irregular and/or forceful heartbeats.</td>
<td>✅</td>
</tr>
<tr>
<td><strong>Very rare</strong></td>
<td>Allergic reactions [shortness of breath, sudden wheeziness, chest tightness, swelling of the eyelids, face or lips, lumpy skin rash or hives]</td>
<td>✅</td>
</tr>
<tr>
<td><strong>Very rare</strong></td>
<td>Seizures [loss of consciousness with uncontrollable shaking (&quot;fit&quot;)].</td>
<td>✅</td>
</tr>
<tr>
<td><strong>Very rare</strong></td>
<td>Lower abdominal pain and/or severe rectal bleeding.</td>
<td>✅</td>
</tr>
<tr>
<td><strong>Very rare</strong></td>
<td>Raynaud’s phenomenon [persistent purple discolouration of hands or feet].</td>
<td>✅</td>
</tr>
<tr>
<td><strong>Very rare</strong></td>
<td>Loss of vision.</td>
<td>✅</td>
</tr>
</tbody>
</table>

This is not a complete list of side effects. For any unexpected effects while taking IMITREX® Nasal Spray, contact your doctor or pharmacist.
HOW TO STORE IT

Keep your medicine in a safe place where children cannot reach it. It may be harmful to children.

Keep your nasal spray device away from heat and light which may spoil them. Always keep your nasal spray device in the carton provided and store between 2°C and 30°C.

If your medication has expired (the expiration date is printed on the treatment pack), throw it away as instructed.

If your doctor decides to stop your treatment, do not keep any leftover medicine unless your doctor tells you to. Throw away your medicine as instructed.

Reminder:

REMEMBER: This medicine is for you. Only a doctor can prescribe it for you. Never give it to someone else. It may harm them even if their symptoms appear to be similar to yours.

REPORTING SUSPECTED SIDE EFFECTS

You can report any suspected adverse reactions associated with the use of health products to the Canada Vigilance Program by one of the following 3 ways:

- Report online at [www.healthcanada.gc.ca/medeffect](http://www.healthcanada.gc.ca/medeffect)
- Call toll-free at 1-866-234-2345
- Complete a Canada Vigilance Reporting Form and:
  - Fax toll-free to 1-866-678-6789, or
  - Mail to: Canada Vigilance Program
    Health Canada
    Postal Locator 0701C
    Ottawa, ON K1A 0K9

Postage paid labels, Canada Vigilance Reporting Form and the adverse reaction reporting guidelines are available on the MedEffect™ Canada Web site at [www.healthcanada.gc.ca/medeffect](http://www.healthcanada.gc.ca/medeffect).

NOTE: Should you require information related to the management of side effects, contact your health professional. The Canada Vigilance Program does not provide medical advice.

MORE INFORMATION

This document plus the full product monograph, prepared for health professionals can be found at: [http://www.gsk.ca](http://www.gsk.ca) or by contacting the sponsor, GlaxoSmithKline Inc.

7333 Mississauga Road
Mississauga, Ontario
L5N 6L4
1-800-387-7374

This leaflet was prepared by GlaxoSmithKline Inc.

Last revised: July 24, 2014

©2014 GlaxoSmithKline, All Rights Reserved

*IMITREX is a registered trademark, used under license by GlaxoSmithKline Inc.*